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EFFICACY OF SULFADOXINE-PYRIMETHAMINE WITH AND WITHOUT 
ARTESUNATE FOR THE TREATMENT OF UNCOMPLICATED MALARIA 
IN MOZAMBIQUE: A RANDOMISED CONTROLLED TRIAL 
Background and rationale 
Malaria accounts for a large public health burden in Mozambique and a 
treatment policy with effective anti-malarials is a. key component of their 
malaria control programme. Artemisinin-based combination therapies (ACTs) 
are now generally considered as the best treatment for uncomplicated 
falciparum malaria; the use of artesunate (AS) in combination with 
sulfadoxine-pyrimethamine (SP) is recommended by the World Health 
Organisation (WHO). Mozambique policy-makers recommended that an ACT 
be implemented and studied in 2003 therefore this was cond ucted to 
compare SP monotherapy with AS, plus in order to provide further 
evidence of available treatment options in the region. 
Trial design and methods 
A prospective multi-centre, open':label, parallel-group randomised clinical trial 
was conducted at 4 public health facilities in Maputo Province, 
Mozambique during the malaria seasons of 2003 - 2004 and 2004 - 2005. 
Eligible patients were aged over 1 year with body weight over 10kg and 
uncomplicated Plasmodium falciparum malaria (parasitaemia less than 500 
000 asexual parasites/ill blood with axillary temperature less than or equal to 
37.5°C or a history of fever). Patients were excluded if they took other anti-
malarials or folate within 7 days, had moderately severe/severe malaria, 
history of G6PD deficiency or allergy to study drugs, or serious underlying 
disease. Patients were randomly assigned to sulfadoxine-pyrimethamine 
(SP): a single oral 25/1.25mg per kg dose on Day 0, with a maximum of 3 
tablets), or artesunate (AS) plus as above, plus single oral 
4mg/kg AS on Days 0, 1 and 2 wjth a maximum daily of 4 tablets). 
study aimed to compare the efficacy of monotherapy SP in 
combination with AS as first line treatment of uncomplicated falciparum 
malaria. primary objective ~as the comparison of the time to treatment 
failure (the relative hazard of treatment failure) between groups using 











transmission modified to a 42 follow up. Randomisation was 
computer-generated with sequential allocation concealed in opaque sealed 
envelopes. Treatments were open-label, however laboratory staff responsible 
for parasite density measurements (in order to determine the primary efficacy 
end point) were blinded to treatment allocation. 
Results 
Four hundred and eleven subjects were randomised to take either SP 
199) or AS plus SP (n=212). 408/411 (99.3%) subjects were included in 
intention-to-treat analyses (SP 198, AS plus 210; 3 subjects were 
excluded as Day 0 parasitaemia could not be confirmed). Kaplan-Meier (KM) 
distributions and survival curves showed that plus had a significantly 
reduced relative hazard of treatment failure compared to SP monotherapy 
(KM estimates for achieving treatment success by Day 42 were 90.4% [95% 
CI 84.9%;93.9%] for SP and 98.0% [95% 94.8%;99.3%] for plus SP, 
log rank 0.0008). In a Cox Proportional Hazards treatment 
with AS plus was found to decrease the relative hazard of treatment 
failure by 80% (adjusted hazard'ratio [HR] 0.2; 95% confidence interval [CI] 
0.1 ;0.6). Other factors found to have an impact on treatment outcome 
included age over 7 years (which decreased the relative hazard of failure by 
70% compared younger age [HR 0.3; CI 0.1 :0.9]), body temperature 
on Day 0 (which decreased the· relative hazard of failure by 50% for each 
additional [HR 1 95% CI 1.1 :2.2]), and having a quintuple dhfrldhps 
mutation (which increased the relative hazard of failure 3.2 fold compared to 
fewer mutations [HR 3.2; 95% CI 1.3;7.5]). A per-protocol analysis including 
354 subjects (SP 1 AS plus SP 177) confirmed findings. 
Conclusions 
combined with SP· significantly decreased the relative risk of treatment 
failure compared to SP monotherapy supporting the literature that combining 
with improves efficacy should efficacy of sufficiently high, 
as the drugs have independent modes of action. Age, body temperature and 












1 IN"rRODUCTION AND LITERATURE REVIEW 
Malaria accounts for a large public health burden in the tropical regions of 
Africa where it is caused primarily -by the Plasmodium falciparum (Pt) 
parasite transmitted by the anopheline mosquito vector. 1,2 Malaria presents 
on a continuum of disease severity depending on, among other factors, 
immunity of the individual to the infection, which itself appears to be partly 
dependent on transmission dynamics inherent within the regions affected? 
Uncomplicated malaria is characterised by non-specific signs and symptoms 
including fever, chills, nausea, and vomiting, malaise, headaches, body 
splenomegaly, thrombocytopenia, anaemia, coughing and 
convulsions, while the severe form of the is usually fatal if 
untreated.4 Particularly vulnerable groups include those with reduced or no 
immunity such as young children, visitors to a malaria region or those who 
may have temporarily migrated from an endemic region and then returned, 
pregnant women, and those with concomitant disease such as HIV/AIOS. 
is made by assessing clinical signs and symptoms and confirmed 
using laboratory techniques rapid diagnostic ROT, or microscopy to 
, . 
detect parasites). 
1.1 burden of malaria in Mozambique 
Mozambique a country in Southern Africa, population circa 20,000,000. 
There is constant (hyperendemic) transmission of malaria, although 
prevalence throughout the country varies greatly according to the season, 
other environmental factors, and use of vector control measures. The 
total number malaria cases reported in Mozambique during 2004 was 
5,610,884, although it is recognized data surveillance methodologies in 
general may weak due to under-reporting and misdiagnoses; malaria is 
usually clinically than definitively diagnosed.2.5 Between 2003 and 
2005 in several districts in Southern Mozambique (when and where this 
particular study took place) malaria prevalence was declining steeply due to 
an intensive intervention of indoor residual spraying (IRS), and ranged from 











1.2 Treatment of uncomplicat~d Plasmodium fa/ciparum malaria 
A policy with an anti-malarial is a component of 
malaria control, the primary aim of such treatment being prevention of the 
progression of uncomplicated malaria to severe malaria and, thereby, to 
preserve life.7 A further aim of appropriate treatment is to reduce the malaria 
infectious reservoir by preventing its transmission from the human host to the 
mosquito vector. is realised through a rapid on asexual parasites, 
preventing the development of gametocytes, parasites' sexual stages and 
thereby reducing infectivity.s 
When considering treatment policies, governments take into account various 
factors such as cost, availability and accessibility, ease use and tolerability 
of the drugs. Furthermore, resistance to anti-malarial in the malaria 
parasites now a critical camp'onent in decision-making. Chloroquine has 
been the most widely treatment for malaria worldwide the 1 
However, due resistance in the paraSite to chloroquine in most regions, 
many governments have had to choose alternative drug pOlicies.9 with 
diseases such as HIV/AIDS, a treatment approach based on combining 
drugs with i+t.o,·.o ... t modes action is now advocated for malaria. 7 
1.2.1 Artemisinin-based combination therapies (ACTs) 
Artemisinin-based combination therapies are now generally considered as 
the treatment for uncomplicated falciparum malaria. This is primarily 
because they act against 4 stages of the development 
effecting a rapid cure and also reduce gametocyte carriage, thus 
transmission of malaria, and anti-malarial 10,11,12 Artesunate (AS) 
has found to be particularly in the of 
uncomplicated malaria.13 There is, as no evidence of clinically relevant in 
vivo resistance to and its use in combination with the longer-acting 
sulfadoxine-pyrimethamine (SP). is recommended by the World Health 
Organisation (WHO) as one of 4 because it is considered affordable 
compared to other From a programmatic point of view, artesunate 
has the unique advantage of the full dose of partner drug being 











In when widely used as monotherapy, SP has a relatively short 
useful therapeutic life. 14 However there is evidence of the superior efficacy of 
treatment that add AS, .to or monotherapies. 15 
The tolerability profile of AS plus SP 
monotherapy, as AS is generally 
found to be similar to that for 
well tolerated except for a 
rare 1 hypersensitivity reactions 16 
1.2.2 Treatment of uncomplicated Plasmodium fa/ciparum in 
Mozambique 
While chloroquine was the treatment policy for uncomplicated in 
Mozambique, evidence poor efficacy throughout tropical Africa 
1980s signalled a to alternatives.9 Amodiaquine plus 
non-artemisinin combination) was subsequently as the 
Mozambique National policy the treatment uncomplicated 
falciparum malaria for in 2005. However, it was 
recommended by policy-makers that an ACT be implemented and studied in 
parallel in a selected area of Southern Mozambique from 2003, as evidence 
regarding their efficacy and while promising, was not yet well 
established in the (South-East African Combination 
was tasked with a SEACAT 
Evaluation/Ministry of Health Inhaca, 2002. 
The SEACAT was' initiated in 1999 as a comprehensive 
evaluation of the introduction of combination therapy 
and was nested in the Lubombo Spatial Development Initiative, a tripartite 
agreement between the governments of South Swaziland and 
Mozambique to improve economic situation in border area 
{Lubomo).6 The Evaluation's role included conduct of in vivo 
. studies at selected in South Africa, Swaziland and 
Southern Mozambique provide data to regarding 
efficacy, safety and emerging. resistance patternsmonotherapy anti-
malarials used in regions and, subsequently, the combination anti-
malarials chosen them. Efficacy of monotherapy as an 
alternative to chloroquine, had been assessed by during an in vivo 











2002. The data showed that cure rates had exceeded the 85% level which 
was considered appropriate for it to be considered for combination with an 
artemisinin-derivative to sustain its useful therapeutic life.? 
1.3 Methodological issues in the analysis of malaria efficacy trials 
It is widely accepted that RCTs be analysed using the 'intention-to-treat' (ITT) 
principle to preserve the random allocation of subjects to treatment group 
regardless of adherence, thereby distributing confounders (known and 
unknown) equally and providing an unbiased estimate of the effect. A 
problem with this method is how to manage missing outcomes. Often those 
subjects who do not compl,ete ~ study are considered treatment failures, a 
'worst case scenario'. This is impractical in malaria efficacy studies as they 
are frequently conducted in populations where migration is common and who 
may be difficult to follow to completion, and spurious results may be found if 
incorrect assumptions are made with regard to the many missing outcomes. 
An alternative is to exclude all non-adherers (those who did not complete the 
study or who did not adhere to the protocol in terms of dose, missed critical 
observations, concomitant medications etc.) and conduct a 'per-protocol' 
(PP) analysis. This may, however, introduce bias as there could be 
systematic associations between protocol compliance and a treatment group. 
Where there are many missing data relating to the outcome and numerous 
protocol violations, problems with the analysis may be compounded by a 
decrease in statistical power if too many subjects are removed. 
It is currently advocated that a survival analysis of time to treatment failure as 
the primary indicator of treatment response in malaria efficacy studies is most 
appropriate.1?,18,19 A benefit of survival analysis over other statistical methods 
such as logistic regression is that every enrolled subject is included, as per 
the ITT principle, and all available data for those who subsequently do not 
complete the study are included to the point where they left the study, 
whereupon the data are censored, removing the necessity to assume 
outcomes. The analysis may then be repeated excluding fully those subjects 
who were major protocol violators, as per the PP principle. However, data to 
the point of a violation may be included until censored increasing the 











2 RATIONALE FOR THE STUDY 
During the malaria seasons of ~003 - 2004 and 2004 - 2005 this SEACAT 
Evaluation randomised controlled trial (RCT) was conducted in Southern 
Mozambique to compare SP monotherapy with the ACT, AS, plus in 
order to provide further evidence to policy makers of available treatment 
options the region, 
The study gave an opportunity to investigate objectives other than efficacy, 
such as safety, molecular markers of SP resistance, gametocyte carriage 
and pharmacokinetic parameters of SP. However, within the limits of a MPH 











The aim of study was compare of SP monotherapy that 
of in combination with AS as first line treatment of uncomplicated 
falciparum malaria in four clinical sites in Southern Mozambique to inform 
Mozambique policy-makers. In order to achieve this aim the following 
outcomes were developed: 
Primary outcome 
., To compare the t9. and risk treatment failure between 
groups, adjusted by characteristics. 
Secondary outcomes 
., To compare the to, and risk of, parasite clearance between 
treatment groups, adjusted by baseline characteristics . 











4 STUDY DESIGN AND RESEARCH METHODS 
This was a prospective multi-centre, open-label, parallel-group RCT 
conducted at Namaacha, Catuane, Boane and Magude public-sector health 












Figure 1: Geographical location of study sites 
14 
Data Sources: LSDI Provincial Malaria Control 
Programmes, Demarcation Board, 












Namaacha and Boane are peri-urban settings while Magude and Catuane 
are rural settings. The study themselves were health centres or Health 
Posts which provide standard 'first-line treatment for uncomplicated malaria 
and refer severe/complicated cases to Matola or Maputo hospitals (Figure 2). 
Catuane is close to the South African border where population movement for 
. \Nork purposes (migration) is known to be prevalent. 
Figure 2: Scenes from the study sites 
Two protocols were developed (with input by the MPH candidate), as initially 
this RCT was nested within an ongoing open label single arm study protocol, 











4.1 Subject recruitment and enrolment 
Inclusion and exclusion criteria were developed using a standard WHO 
protocol for assessment of for anti-malarials in low to moderate 
malaria transmission intensity and contra-indications for treatments in 
terms of and/or for validity of the proposed analysis.22,18 
Specifically; male and non-pregnant (or breast-feeding) female patients over 
the age of 1 year and over 10kg body weight with symptoms of malaria who 
presented routinely at the clinics were invited to give informed consent prior 
to sequential screening for Plasmodium falciparum infection by rapid 
diagnostic (RDT: Immunochromatographic ICT P.f®., SA 
Scientific). A physical examination assessed eligibility. 
Those diagnosed with uncomplicated acute falciparum malaria 
parasitaemia of up to 500 000 asexual parasites/ill blood with an axillary 
temperature of greater than or to 37.5"C or a medical history fever 
(defined as within the previous hours) and who close enough to the 
study for reliable follow up, were deemed for inclusion. 
patients who .. """"""". during the medical history that 
any the past 7 were 
excluded (including drugs with inherent anti-malarial properties though not 
for treatment of malaria, s'pecifically cotrimoxazole, trimethoprim, 
chloramphenicol or tetracyclines). In addition, patients who had received 
folate in the past 7 days (due to its role as a antagonist to the antimalarial 
subsequently published) or were likely to require any of the 
2."",,,,,,, mentioned drugs the study , or who were ill 
(according to WHO Criteria) or considered, in opinion of the investigator 
or designee, to have moderately severe malaria (e.g. prostration, repeated 
vomiting, dehydration) or danger signs, had a known history of G6PD 
a history of allergy to any of study drugs (including other 
sulphonamides or artemisinin or a underlying 
se~ise that in the opinion of the clinic team and/or Principal Investigator 
would make the patient unsuitable for the study in terms of safety or 











4.2 Study treatments 
4.2.1 Dosing schedule 
subjects were randomised to receive a weight-appropriate dose of 
observed treatment with monotherapy (a single oral 25/1 per kg 
on Day 0, with a maximum of 3 tablets) or AS plus SP (a single oral 
dose of SP as above on Day 0 and oral 4mg/kg doses AS on Days 
0, 1 and 2, with a maximum daily dose of 4 tablets). SP was 
Fansidar® (Roche, South Africa) while the was co-
packaged as Arsudar® (Sanofi, Gauteng, South Africa) ............ ,;"' ....... were be 
given as whole tablets administered with water. 
A dosing schedule (Table 1) was determined by derivation of an optimal 
regimen allows for AS to blister-packed with SP in whole 
tablets, from a CDC of a 55,000 African malaria patient dataset 
which made recommendations tq minimise over- and under-dosing (Personal 
communication A Terlouw, subsequently published)7: 
Table 1: Doses of artesunate (AS) and sulfadoxine-pyrimethamine (SP) 
Mass (kg) Approximate SP tablets 50mg artesunate tablets 
age (years) (all subjects) plus group only) 
DayO Day 0 Day 1 iDay2 
10-20 1-6 1 1 1 1 
21- 35 ~13 2 2 2 12 
> ~§ 14 + 3 4 4 4 
4.2.2 Randomisation 
A UCT statistician "' ..... ,,, .. ""to"'l"l computerised random allocation schedules 
(AS 
each of the two protocols, which were withheld from the sites' study teams. 
clinic had a schedule which allowed for equal randomisation of subjects 
between SP and AS plus within blocks of ten. (4 in total) of 
random allocations was divided sequentially into three sections to represent 
the three weight-based dosing levels such that, within each level, there 
was an equal chance of a subject being' allocated SP or AS plus SP. 
Treatments were concealed in opaque padded envelopes which were 
packed, sealed and labelled with sequential numbers by UCT Study 
Manager (MPH candidate). Once site staff selected the next available 











label as manufacturer was not to provide dummy tablets. Open-label 
spare were available for re-dosing in case of vomiting within an 
hour of treatment. 
4.3 Visit schedule 
The visit schedule was chosen as recommended in the standard WHO 
protocol for the assessment of in vivo therapeutic efficacy of antimalarials, 
however with extension to a day follow up due to the long elimination half 
of 22 
4.4 Study assessments 
Enrolled subjects were seen on Day a and then asked to return to the clinic 
on Days 1,2, 7, 14,21,28 and for assessments relating to clinical and 
parasitological end points: axillary temperature, asexual parasite density, 
haemoglobin concentration (the, latter two by finger prick blood 
sample), and clinical signs and symptoms to capture adverse events, data 
regarding resolution of symptoms and concomitant medications. 
In addition, dried blood samples (by finger prick sample) were taken at 
visit to identify parasite mutations associated with resistance to SP such that, 
for those participants who experienced parasitological failure during the 
day follow up period. polymerase chain reaction (peR) could determine 
whether this was re-infection with a new parasite or recrudescence the 
original infection. 
Subjects were encouraged to return for unscheduled visits if they felt unwell. 
Further detail regarding efficacy assessments is given below: 
4.4.1 Parasitology 
Identification of Plasmodium falciparum and Plasmodial parasites was 
according to a standardized WHO methodology.25 
identification was made from a -thin smear, while asexual parasite density 
was calculated by counting the number of asexual on a thick blood 
smear stained with Giemsa (assuming 8000 per IJI blood). All 











Slides were labeled, air dried and stored in slide boxes at room 
according to a defined process, prior to archive. 
4.4.2 Rapid diagnostic tests, medical history, concomitant medication, 
adverse event data 
Standard training in how staff would elicit medical histories and the 
collection of concomitant medication and adverse event data was given prior 
to and during the study by MPH candidate and/or monitor. 
correct method for using the rapid diagnostic 
microscopist. 
4.4.3 Molecular analyses 
was ensured by a senior 
Samples were labeled according a defined process and were air dried 
away from dust, excessive humidity, insects & direct sunlight for 1 hour, prior 
to placement in a plastic zip-lock sample bag with desiccant. The bags 
containing samples from each visit were kept brown envelopes labeled 
with subject/visit details and in pl stic boxes until collection by 
monitor for dispatch to the laboratory. 
, 
used highly \larlahil.c:o proteins (MSPI, MSPII and GLURP) to 
re-infection form recrudescence, which is more accurate than the 
methodology used in some publications which only one or two 
proteins.26 
SP mutational analysis was conducted by Medical Research Council, 
Durban according to a standard methodology. Primers, PCR amplification 
conditions and restriction endonucleases were used to detect polymorphisms 
in the dhfr (codon 51, 108, 164) and dhps (codon 436, 437, 540 and 581) 
genes Digestion 
products separated on a 2% agarose using electrophoresis were 
visualised and photographed using a MiniSIS documentation system and the 
genotype of each codon was cl~ssified as either pure wild, pure mutant or 












subjects who experienced clinical or parasitological failure, according 
to standard definitions (described under section 4.7), were withdrawn and 
given rescue treatment with quinine. Other reasons for withdrawal included: 
1\ Any clinical deterioration other than treatment failure: 
1\ Any serious adverse event requiring treatment withdrawal or resulting in 
inability to continue study assessments . 
. 1\ Any allergic reaction or skin rash presenting during the treatment courses, 
whereupon the site staff were required to stop the study treatment, 
manage the allergic reaction, and counsel study subjects against 
repeated treatment with the same drugs in the future. 
• Concomitant nrll'>c;:rn any drugs that may interfere with study 
analysis or present a safety concern for the study subject. 
, 
4.6 Sample size and power 
The sample sizes required for of the protocols independently were 
calculated assuming an adequate clinical and parasitological response 
(ACPR) rate of 75% for SP and 90% for AS plus SP (with a confidence 
interval of 95%, and 80% power) indicating that 100 per treatment group per 
protocol (400 subjects in total) were needed. Although the first protocol in 
2003-2004 Namaacha and Catuane clinics did not achieve the expected 
recruitment rate, the addition of data from the 2004-2005 protocol allowed the 
. 
overall sample projections to be exceeded. 
4.7 Efficacy endpoints 
The responses to treatment were standard WHO definitions relevant for low 
to moderate malaria transmission intensity modified for a day follow 











Table WHO classification of response to treatment modified for 42 
day follow up 




Adequate Clinical and 
Parasitological 
, (ACPR) 
• Development of f'I~n,f'I.:>r 
Day 2 or Day 3, in 
• Parasitaemia on 
or severe malaria on Day 1, 
of 
of 
on Day 3 with axillary 
• P.:ar,,,",,,jit.:> ..... i.:a on Day 3 2: 25 % of count on 
2: 37.5 "e 
4 to 42, without 
early treatment failure 
Late Parasitological Failure (LPF) 
• Presence of parasitemia on any day from Day 7 to Day 42 
and axillary temperature < 37.5 "e, without previously meeting 
any of the criteria of early treatment failure or late clinical 
failure 
of on Day 42 of axillary 
T':>I"I'In.:>r.:aT, without previously meeting any of the of 
treatment or clinicsl failure or late 
parasitological failure. 
However, the study was concluded World Anti-malarial 
Network (WARN) has proposed an expanded description of possible 
outcomes for subjects enrolled in malaria efficacy studies so that data may 
be collated from numerous study sites in a standard format for a global 
database. While the WARN definitions are consistent with the above WHO 
guidelines in terms of the efficacy endpoints, it expands them and makes 
provision for how protocol violations, and other reasons for non-completion of 











Table 3: WARN description of possible outcomes on the last day of 
follow up for patients enrolled in malaria efficacy studies 
I Variable code Description 
Patients who complete the study 
0 ACPR 
1 ETF and death 
2 ETF with severe malaria 
3 ETF with danger signs 
4 ETF with Parasitological Criteria (day 2 > day 0 or day 3 >25% day 0) 
5 ETF with Clinical Criteria (documented fever and parasitaemia on day 3) 
6 , ETF not otherwise specified (for when details of why ETF classified not available) 
,7 L.CF and Death 
8 I LCF with Severe Signs 
9 F with Danger Signs 
10 LCF with fever (either measured or subjective) 
, 11 LPF 
12 LPF/LCF Indistinguishable, (for when details of LCF/LPF classification not ""~"~W''''I 
Patients who do not complete the study 
13 Adverse event reCjuirinj;J change in therapy prior to completion of full dose 
14 Protocol violation 
15 Death not due to malaria 
16 Lost to follow-up 
17 Use of other antimalarials outside of study protocol in the absence of 1-1""<:2':>'1<:2<01111'" 
. 18 Withdrawal of consent by patient prohibiting further follow-up 
, 19 
" initiated withdrawal from further follow-up 
20 Patient who does not complete follow-up for any other reason not listed above 
21 Enrolment Violations 
To enable SEACAT studies to contribute to the global databases, data from 
this RCT were coded and described according to WARN guidelines. 
However, to low numbers of subjects in some WARN categories in this 
study, data were grouped according to the WHO classification for subjects 
who completed the study (WARN variables 0 to 1 and in three further 
summary for subjects who did not complete (within WARN 
variables 13 to 21): 
Patients who completed the st':Ady 
• ACPR (WARN variable 0) 
• ETF (WARN variables 1 to 6) 
• L TF-LCF (WARN variables 7 to 10) 



















Patients who did not complete the study 
• Adverse event requiring change in therapy prior to completion of full dose, 
protocol violation, death not due to malaria (WARN variables 13 to 15, 1 
20,21) 
• Lost to follow up (WARN variable 16) 
• Withdrawal of consent by 
(WARN variables 18 and 19) 
or investigator-initiated withdrawal 
4.8 Data collection and management 
Baseline characteristics and data from study assessments were recorded on 
study-specific source templates (Appendix 1), designed by the MPH 
candidate, which supplemented any routine clinic notes. Key source data 
necessary for the analyses were transcribed onto case forms (CRFs, 
Appendix 2), designed by the MPH candidate, which were 100% verified on-
site by the UCT monitor and submitted for double data entry into an MS 
r\"""""..,,,,,,,, 2000 (Microsoft Corporation, Seattle, USA) database at the Medical 
Research Council Malaria Lead Programme in Durban. Written data queries 
were raised through both a manual review by the MPH candidate and by 
computerised validation checks specified by the MPH candidate. These were 
clarified with site staff in order to clean the database. Laboratory data from 
the MRC were recorded electronically (MS Word or MS Excel). 
Data were imported from MS Access or MS Word/Excel into Stata/IC 10.0 
(StataCorp Station~ USA) and cleaned by the MPH 
candidate through cross-referencing relevant variables, thereby generating 
written queries which were resolved by rcoTt::lrcon 
data prior to updating the STATA file. 
to the source and/or 
Outcomes, time-to-eventlcensoring indicators and explanatory variables were 
programmed in STATA where Medical history and concomitant 
medication data were coded using the International Classification of 
Version 10 (ICD10) and a study-specific coding dictionary developed using 











4.9 Handling of protocol violations and missing data 
Major protocol violations were defined as: 
411 Subjects who study Days 1, 3 (AS plus SP) or 2,3 (SP) 
411 Subjects who took a concomitant medication with antimalarial activity 
or folic acid 
411 Subjects whose Day 42 visit was more than 3 days late 
411 Incorrect dose administered 
411 Repeat dose due to vomiting (although directions for managing this 
were provided in the protocols) 
Except for Day 42 (as indicated, above), visit windows were not applied as 
actual dates of assessments were used in the survival analyses, Similarly, 
data were not censored due to missed visits as it is assumed that intensive 
monitoring would any history of malaria symptoms or treatment 
since the visit. 
For safety reasons an attempt was made to follow subjects to completion 
of the actual Day 42 visit or assessment prior to follow up 
despite protocol violations that may have impacted on the efficacy analysis . 
. Individual missing data fields were automatically or manually dropped from 
the analyses where appropriate. subjects' Day 0 parasitology 
were lost after a positive for malaria, but prior to a parasite density 
measurement being documented, and these subjects were excluded from all 
efficacy analyses. 
4.10 Ethical considerations 
Both protocols and related documentation were approved by the University of 
Cape Town Research Ethics Committee and the Ethics Committee for the 
Mozambique Ministry of Health prior to study commencement (Appendix 3). 
The study was conducted in accordance with the South African Clinical Trials 
Guidelines 2000 which are on the principles of the Declaration of 
Helsinki and the International Conference on Harmonisation for Good Clinical 










Underpinning good clinical practices are the ethical principles of autonomy 
(respect for the dignity of the person), beneficence (benefit) and non-
maleficence (absence of harm) to the research subject, and justice (equal 
distribution of risks and benefits between communities).31 
were integral to the study design and its management. 
principles 
In terms of autonomy, written informed was obtained from each 
subject or their guardian. Study were given extensive training in how 
to request informed consent from subjects who could be considered 
vulnerable they had limited financial resources, may have been 
illiterate or unfamiliar with their rights regarding clinical research, and who 
also needed to make a quick decision whether to enroll in the study while 
they were unwell. Illiterate patients marked 'X' in the presence of an 
independent literate witness who signed the consent documentation. The 
team was aware that informed consent was an ongoing process throughout 
the study and that the subjects' could leave the study at any time with no 
detrimental impact on their obtaining future health care at the health centre. 
The importance of ensuring confidentiality regarding subjects' participation 
and their personal data was also stressed. 
While the study was designed expecting that the efficacy of AS plus SP 
would be different to that of SP monotherapy. this was not established in the 
region. had already been found to have acceptable efficacy there, which 
was far superior to chloroquine .. the first line treatment policy at that time. 
Both study treatment groups were followed closely to ensure that possible 
relating to adverse drug reactions or lack of efficacy would be 
detected promptly and managed appropriately. 
The study sites were selected, .after discussions with policy-makers in 
Mozambique, to be where there was a significant malaria risk and, if better 
treatment policy could be established as a result of the study, the benefit to 
the communities involved may be significant. Community involvement was 
sought to establish dialogue between the research teams and community 
leaders, and to convey the possible impact of the results on future treatment 
policy. In addition an overall objective of the SEACAT Evaluation was to build 










the teams and/or the clinics or by improving infrastructure. and above 
training in research methodology and ethics provided to during the 
study. several post-graduate study opportunities were available. During 
the study, useful equipment or services (such as microcopy for 
parasitological diagnosis of malaria and Hemacue® equipment for the rapid 
accurate determination of haemoglobin) were made available the clinics 
which did not usually have them and, after the study was completed, some of 










5 STATISTICAL ANAL VSIS METHODS 
Although the primary outcome was analysed using survival methods, the 
overall treatment response of subjects who completed the study were 
summarized by treatment group and proportions compared using Chi-square 
5.1 Demographic and clinical characteristics 
Some characteristics were prospectively identified as potential factors 
and/or confounders: age, haemoglobin, of anaemia/severe 
anaemia (WHO 2001), parasite dhfr/dhps mutations, gender, parasite 
density, body temperature, body'weight, mg/kg dose of pyrimethamine a 
measure of both pyrimethamine and sulfadoxine doses), mg/kg of 
artesunate, study site. Other characteristics were identified retrospectively 
on a subsequent literature review: recent history of diarrhoea or 
vomiting, diarrhoea in the first 24 hours or during days 2 to 7, recent history 
of vomiting combined with fever on Day 0, vomiting within 1 hour of 
treatment, concomitant therapy with a drug having antimalarial properties.27,59 
Categorical variables were summarised using frequencies and percentages. 
Continuous variables were summarised using means and standard 
deviations if normally distributed, or alternatively using medians and inter-
quartile ranges if non-parametric, and distributions were examined using 
histograms. Correlations were, tested using Pearson's product moment 
correlation coefficient (or Spearman's rank correlation if not normally 
distributed) . 
5.1.1 Differences between gro,ups and across study sites 
To explore associations between baseline characteristics and treatment 
group (in order demonstrate successful randomization). baseline data 
were compared using Chi-square or Fisher's exact tests (if and 
Student's two sample t-tests or the Wilcoxon rank sum test (as appropriate, if 
continuous). between the four study sites were explored using 
Chi-square or Fisher's exact tests (if categorical) and Kruskal-Wallis (if 










5.1 Association with completion status 
To further investigate selection bias, the baseline characteristics of subjects 
who did not complete the study were neither successfully treated nor 
considered treatment failures) were compared with those who did complete 
the study using Chi-square or Fisher's exact tests (if categorical) and 
Student's two sample t-tests or the Wilcoxon rank sum test (as appropriate, if 
continuous). 
5.2 Survival analysis methodology 
Survival analysis currently recommended for analysing malaria efficacy 
studies (section 1.3) therefore the Kaplan-Meier (KM) method was used to 
generate time to event (treatment failure or parasite clearance) distributions 
and survival curves for the two treatment strategies, and these were 
compared using a log rank 
Associations between response and baseline characteristics (other potential 
risk factors) were estimated usil}g Cox's Proportional Hazards Regression. 
These risk factors were modelled in a univariate fashion and the variable with 
the most significant association chosen on which to build the model. 
Thereafter, remaining explanatory risk factors were added manually in a 
forward stepwise manner for comparison with the best model by 
evaluating the likelihood ratio (LR) statistic and Aikaike's Information Criterion 
(AIC). Finally, the main effect (treatment group) was included. Automated 
stepwise models were compared with those obtained from the manual 
process. Interaction terms were generated where appropriate and interpreted 
for Significance. Models were interpreted using hazard ratios. 
Cox-Snell residuals were generated to assess overall fit of the models and 
outliers/influential observations were identified using rescaled Martingale 
(deviance) and ESR residuals. The assumption for proportional in 











5.3 Primary outcome analysis: time to treatment failure 
5.3.1 Intention-to-treat analysis 
For the intention-to-treat analysis the time to treatment failure was defined as 
time from Day 0 until the actual day of treatment failure due to 
recrudescence (ETF, LTF-LCF or L TF-LPF). Subjects were considered as 
not yet failed treatment if they achieved an ACPR by actual Day 42 or were 
at last evaluable assessment due to loss to follow up, 
withdrawal or re-infection with malaria parasites. 
Subjects' use of concomitant therapy with another drug having inherent 
antimalarial properties, and a repeat dose of study drug due to vomiting 
within 1 hour of treatment, were· both included as potential risk factors. The 
protocols also included provision for a repeat half dose if vomiting occurred 
within % an hour but to low numbers any repeat dosing occurrences 
were combined for the analyses. 
5.3.2 Per-protocol analysis 
For the per-protocol analysis, the time to treatment failure was again defined 
as the time from Day 0 until the actual day of treatment failure due to 
or Subjects were considered as 
not yet failed treatment if the  achieved an ACPR by actual Day 42 (± 3 
days) or were censored at the last evaluable assessment due to loss to 
follow up, w.ithdrawal or re-infection. 
, 
were excluded fully for subjects who missed a study dose and/or Days 
2 and/or 3 (days where key protocol withdrawal criteria were applied) or who 
did not otherwise take the dose according to the protocol, including those 
who had a repeat dose of study drug within 1 hour, due to vomiting. 
Furthermore, data were censoreCJ at the last evaluable visit if subjects took a 
prohibited concomitant treatment with antimalarial properties or when Day 42 
was more than 3 days late (Le. data would censored at Day 28 if that was 
the last visit "'0,,""1"'0 a Day 42 visit that was more than 3 days late). Since this 
study was concluded it was recommended that erythromycin be prohibited in 
malaria efficacy studies due to its weak anti-malarial activity, therefore 











5.4 Secondary outcome analyses 
5.4.1 Time to parasite clearance 
For time to parasite clearance the data were analysed both on an intention-
to-treat and a per-protocol basis using the same datasets as described above 
for the primary outcome. definition of time to clearance was the 
time from Day 0 to the first of 2 consecutive zero parasite density readings. 
5.4.2 Fever clearance 
For fever clearance, data were restricted to a subset of subjects who were 
documented as having a fever on Day O. Fever clearance time was defined 













6.1 Study subjects 
6.1.1 Enrolment and follow-up 
Four hundred and eleven subjects were enrolled between the 4 study sites 
from January 2003 to January 2005 and were randomised to take either SP 
(n= 199) or AS plus SP (n=212) 3). All subjects took one 
dose of study medication although 1 subject (SP) could not tolerate the dose 
and was withdrawn for parenteral treatment with quinine. 332 (80.8%) 
subjects were followed to study completion despite protocol violations such 
that some data were ultimately excluded from, or censored in the analyses. 
nominal Day 50 subjects overall (12.2%) were lost to follow up (the 
main reason reported to be movement out of the study area due to work) 
while 2 (0.5%) were withdrawn due to adverse The lost to follow up 
percentages were similar between treatment groups (SP, 11.6% AS plus SP, 
12.7%). A further were for malaria according to the 





Total followed to study endpoint (n::;:157) 
'Lost to follow up (n=23) 
-Rescued but found to have re-infection 
by PCR (n=18) 
-Withdrawn due to adverse event 
- discontinued on day 0 as could 
not tolerate oral medications (n=1) 
Figure 3: Subject flow 
31 
Total followed to study endpoint (n=175) 
-Lost to follow up (n=27) 
-Rescued but found to have re-infection 
by PCR (n=9) 
-Hospitalised due to adverse 










6.1.2 Protocol violations 
The following protocol violations were found (subjects may have had more 
than 1 violation). There were no significant differences between groups: 
Table 4: Protocol violations by treatment 
Violation SP (no.) AS plus SP (no.) 
Dayo parasitology slides lost 1 2 
Dose incorrect 4 4 
Missed a study dose and/or visits on days 2/3 9 15 
i Disallowed medication (folic acid) 2 I 1 
Disallowed medication (chloroquine) 0 1 
Disallowed medication (cotrimoxazo.le) 2 3 
i Disallowed medication (doxyxycline) 1 0 
Disallowed medication (erythromycin)'" 18 18 
Repeat dose of study drug due to vomiting 7 13 
'" Added to prohibited medication list retrospectively 
Overall treatment response 
Three RDT positive subjects were removed from all analyses as Day 0 
were lost. Of subjects followed to completion 87.9% in SP arm and 
97.7% in the AS plus SP arm achieved an ACPR (P=0.0008). There were 
recrudescent treatment failures and 7.6% were withdrawn for treatment 
failure yet subsequently found by PCR to have been re-infected. were 
differences between groups for all categories for ETF while the 
difference between treatments for re-infection was not significant. (Table 
Overall treatment response by treatment 
SP n(/%) ASSP n(/%) 
138/156 (87.9) 169/173 (97.7) 













*2-sample test of proportions **denominator includes those found to be re-infected by peR 












6.3 Primary outcome analysis: time to treatment failure 
6.3.1 Intention-to-treat (ITT) analysis 
408/411 (99.3%) subjects were included in the intention-to-treat (3 
subjects were excluded completely as malaria could not confirmed. Figure 
4). 
SP enrolled, n=199 
Included 98) 
Excluded for protocol violation: 
• Missing Day 0 parasitology 
) 
'''' ... ,,, ........ ,.1'1 at last visit if (n=42): 
• Lost to follow up 
• Re-infection 
• Withdrawn due to AE (couldn't 
AS 
Included 0) 
Excluded for protocol violation: 
• Missing Day 0 C!itf'llf'lnu 
(n=2) 
at visit if (n=37): 
• Lost to follow 
• Re-infection 
• Withdrawn due to 
(pneumonia) 
Figure 4: Subjects included in ITT analysis of primary outcome by 
treatment 
Histograms of data from all subjects show haemoglobin, temperature, mglkg 
dose of SP and AS to be normally distributed while age, duration of malaria 
symptoms, parasite density and weight were not. Parasite density was log10 
transformed when it took a bimodal distribution indicating a possible 
interaction with (an)othe  variable{s) (Figure 5). 
As anticipated, there was correlation between and weight (Spearman 0.9 
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figure 5: Histograms of continuous baseline characteristics, all 
subjects 
There were no differences between the treatment groups in terms baseline 
and clinical characteristics, including the 3 subjects subsequently removed 
from all analyses (Table 6a). Age was further explored to find whether a 
binary variable would more informant and if so to determine an optimal 
cut-off for a categorical variable. In areas of moderate to high intensity 
malaria transmission younger children are at greater risk treatment 
generally compared with older children and adults.33 
Differences in haemoglobin, temperature, mg/kg of SP and AS, age, 
weight, parasite density, duration of malaria symptoms, history of vomiting 
(alone and combine with fever) and mutations were found between study . 
sites (Table 6b). The lower 0 10910 density for Catuane subjects 
compared to other sites may have contributed to the bimodal distribution 











Table 6a Baseline and clinical characteristics by treatmentf aU subjects 
WHO 2001 
N/a Not applicable 
" Student's two t-tests #Wilcoxon rank sum test or Fisher's exact tests 
Table 6b: Baseline and clinical characteristics by study site, aU subjects 
WHO 2001 
N/a Not applicable 
" Student's two 
35 
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Figure 6: Histograms of log parasite density day 0 by site, aU subjects 
When data were explored in terms of associations between the baseline 
characteristics and whether or not subjects completed 
differences were found. 
study, no 
When Kaplan-Meier distributions and survival curves were generated, 10 
subjects' observations ended before entering the analysis, as they were 
censored immediately after Day O. The Kaplan Meier estimates for achieving 
an ACPR by Day 42 were 90.4% (95% CI 84.9%;93.9%) for SP and 98.0% 
(95% CI 94.8%;99.3%) for AS plus AS plus showed a significantly 
reduced relative hazard of treatment failure compared to SP monotherapy 
(log rank 0.0008) (Figure 7 and Table 7). 
was a greater difference- observed between treatments by Day 45; 
ACPR following SP, 83.4% (95% CI 63.9%;92.9%), AS plus SP, 98% (95% 















0 3 7 14 21 28 4245 
analysis time 
at risk 
trt::: SP 192184 178 168 163 152 1373 
trt ::: SP/ART 206202 196 189 185 177 16510 
Figure Kaplan Meier survival curves for time to treatment failure, ITT 
dataset 
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A univariate Cox regression model aimed at estimating unadjusted 
treatment showed a decrease of 80% in the relative risk of treatment 
failure for AS plus SP compared to (Hazard ratio 0.2, 95% CI 0.1 ;0.6, 
p=0.003). The following univariate relationships were found for the other 
factors (Table 8): 
Table 8: Time to treatment failure univariate analyses of potential risk 
factors, ITT dataset 
Variable Hazard ratio 95%CI 
Age> 7 years vs. age :s 7 years ill 0.1-0.8 Anaemia, presence vs. absence 0.8-4.1 
Severe anaemia, presence vs. absence 2.6 0.4-19.2 
AS total dose (mg/kg) 0.7 0.5-1.7 
Pyrimethamine total dose (mg/kg) 1.1 0.6-1.9 
Diarrhoea in the first 24 hours post-dose, 0.9 0.1-7.5 
presence vs. absence during that time 
Diarrhoea between days 2··7 presence vs. 1.5 i 0.2 .. 11.3 
absence on these days 
Duration of malaria symptoms before Day 0 1.0 0.9-1.2 
(days) 
Gender, male vs. female 1.4 0.6-3.3 
Haemoglobin Day 0 (g/dL) . 0.9 0.8-1.1 
Log10 parasite density (per IJI blood) 1.7 1.1-2.7 















i Site Catuane vs Boane 1 Unable to estimate due to no treatment failures at Catuane 
M~gude vs Boane 1.3 OA-4·1 
Namaacha vs Boane 3.0 0.9-9.8 
Namaacha (compared to all other sites) I 3.1 1.3-7.2 
Temperature Day 0 (OC) 11.7 lli.-2.4 
History of vomiting vs. no history of vomiting 1.1 .2-4.5· 
• History of vomiting combined with fever Day 0 1.3 0.2-9.7 
vs. no such combination 
Repeat dose of study drug due to vomiting 0.93 0.1-6.9 
Weight (kg) 0.97 0.95-1.0 
. Use of other drug with anti-malarial activity 1.2 0.4-4.0 
significant variables in bold type 
Using these univariate models as a starting point, several multivariate models 
were considered and compared to find the subset of combined risk 
factors that are predictive of the hazard of treatment failure (Table 9). 
variables relating to concomitant medication with another drug having 
inherent antimalarial activity and repeat dose of study drugs due to vomiting, 
which were only tested in the' analysis, were both not significantly 



















Table 9: Time to treatment failure best model without treatment, ITT 
dataset 
Variable Hazard ratio p 
0.4 0.033 
3.6 0.003 
1.6 1.1 0.011 
This table shows a significant negative association between and the time 
to treatment failure, indicating that those over 7 years have a 60% decreased 
relative hazard of failure compared to younger children. There were 
significant positive associations for both a of a quintuple mutation 
and baseline temperature with the outcome, suggesting that those subjects 
with a quintuple mutation have a greater than 3-fold increased relative hazard 
. of failure compared to those with fewer mutations. There was a 60% 
increased hazard of failure for every 10 increase body temperature. 
Table 10 presents the model with treatment group added to the selected 
of factors ....... ..:.C>..:...,,~..:.rl in addition of treatment did not 
significantly change the previous model, and the association between 
treatment and failure, when modelled with the explanatory variables, was 
almost identical to that found when unadjusted. Interaction terms between all 
final variables selected were t~sted and no significant interactions were 
found, indicating that the treatment effect is the same for both the and 
mutations categories and all temperatures. 





1 1.1-2.2 0.020 
above show that AS plus SP decreases the relative hazard of 
treatment failure by 80% with SP monotherapy. Other important 
factors that also have an impact include being oyer 7 years (which 
decreases the relative failure by 70%), the body temperature on 










additional 1°C) and having a quintuple mutation (which increases the relative 
hazard of failure 3.2 fold compared to fewer mutations). 
Temperature on Day 0 was chosen during model·building due to the strictly 
systematic method used had a univariate statistical 
significance). However parasite density, which is also a known indicator of 
disease severity, has been found to a significant predictor of treatment 
failure in other studies.34 In our study IOg10 density had a similar 
univariate association with the relative hazard of treatment failure as for 
temperature therefore the final model was tested substituting parasite density 
for temperature, whereupon it was not found to be a significant factor and 











6.3.2 Per-protocol (PP) analysis 
354/411 (86.1 %) subjects were included in the per-protocol analysis 
8). 
baseline 
were no differences between the treatment groups in terms of 
clinical characteristics (Table 11). 
SP enrolled, n=199 
Included 77} 
Excluded for protocol violation (n=22): 
• Missing a data 
) 
• Missed day 2 or 3 or dose 
incorrect (including re-dose) 
(n=19) 
• Prohibited concomitant· 
medication (n=2, folate) 
Censored at last evaluable visit if (n=38): 
• Lost to follow up . 
• Re-infection 
• Withdrawn due to AE ' 
• Took anti-malarial 
• Day 42 > 3 days late : 
Included {n=1 
Excluded for protocol violation (n=35): 
• Missing day a data 
(n=2) 
• Missed day 2 or 3 or dose 
incorrect (including re-dose) 
(n=32) 
• Prohibited concomitant 
medication , folate} 
Censored at last evaluable visit if (n=28): 
• Lost to follow up 
• Re-infection 
• Withdrawn due to 
• Took anti-malarial 
• >3 
Figure 8: Subjects included in PP dataset analysis by treatment 
Table 11: Baseline and clinical characteristics by treatment, PP dataset 










When Kaplan-Meier distribution~ and survival curves were generated, 
subjects' observations before entering the analysis, as they were 
censored immediately after Day O. Treatment with AS plus SP was found to 
prolong the time to treatment failure compared to SP monotherapy (log rank 
0.005) as shown by Kaplan-Meier curves (Figure 9) and survival 
estimates (Table 1 
Survival estimates by treatment group 
Ie 
d 
0 3 7 14 21 28 42 45 
analysis time 
Number at risk 
trt:: SP 162153 146 135 131 121 110 2 
trt:: SP/ART 163159 156 152 148 138 126 3 
Figure Time to treatment failure KM survival curve, PP dataset 
Table 12: Time to treatment failure KM survival estimates, PP dataset 
Days 
N Survivor function 
% and 95% 
N Survivor function 
% and 95% CI 
The data show that the Day 42 ACPR estimates were 90.4% (95% CI 
84.4%;94.2%) and 98.1% (95% CI 94.2%;99.4%) for AS plus 










change in these 
at Day 45 seen in 
obser,ved by Day 45, unlike the greater difference 
ITT dataset. 
A univariate Cox regression model aimed at estimating the unadjusted 
treatment effect showed that the relative hazard treatment failure 
decreased by 80% on treatment with plus compared to 
monotherapy (Hazard Ratio 95% CI 0.1;0.7, p=O.011), as was found in 
the intention-to-treat analysis. 
The following univariate relationships were found for the other risk factors 
(Table 13): 
Table 13: Time to treatment failure univariate analyses of potential risk 
factors, dataset 
Variable Hazard ratio 9S%CI 
Age> 7 years vs. age S 7 years 0.2 0.1~0.6 
I Anaemia, presence vs. absence 2.1 0.8-5.4 
i Severe anaemia, presence vs. absence 3.7 0.5-27.6 
AS total dose (mg/kg) O.S 0.3-0.8 
Pyrimethamine total dose (mg/kg) 1.1 ·0.3-3.6 
Diarrhoea in the first 24 hours post-dose, 1.2 0.2-8.8 
presence vs. absence during that time 
• Diarrhoea between days 2-7 presence vs .. 1.6 0.2-12.3 
absence on these days 
Duration of malaria symptoms before Day 0 1.0 0.8-1.2 
i (days) 
Gender, male vs. female 1.1 0.4-3.0 
Haemoglobin Day 0 (g/dL) 0.9 0.7-1.1 
LOgi0 parasite density (per 1.11 blood) • 2.3 1.3-4.0 
Presence of a quintuple mutation vs fewer 13.4 1.3-8.7 
mutations 
• Season 2004 vs. 2003 0.6 0.2-1.8 
















Site Catuane vs SUdIII'::: I Unable to estimate due to no bedlillent failures at Catuane . 
Magude vs Boane 1.1 ·0.3-3.8 0.858 I 
Namaacha vs Boane 2.3 0.7-8.1 0.198 J 
Temperature Day 0 (ec) 1.9 1.3-2.7 0.002 
History of vomiting vs. no history of vomiting 1.4 0.3-6.3 0.626 
i History of vomiting combined with fever Day 0 2.0 . 0.3-15.1 0.500 
I vs. no such combination 
Weight (kg) 0.97 0.94-1.0 0.047 










statistically significant univaria~e association was found between the mg/kg 
dose artesunate and the relative hazard of treatment failure (p=0.004) 
which is related to a particular influential outlying study subject who was an 
early treatment failure on Day 1 and only a Day 0 dose. The mg/kg 
artesunate variable could not thereafter be brought into the model. 
Using these univariate models as a starting point, several multivariate models 
were considered and compared to find the best subset of combined risk 
factors that are predictive of the relative hazard of treatment failure (Table 
14). 
Table 14: Time to treatment failure best model without treatment, PP 
dataset 
Hazard ratio . 95%CI 
0.2 0.1-0.6 0.005 
4.0 1 0.6 0.005 
1.7 1.2-2.6 0.008 
0.3 0.7-1.1 0.072 
As found in the intention-to-treat table indicates that those over 7 
years have a decreased relative hazard of failure compared to younger 
children (by 80%) while those subjects with a quintuple mutation have an 
increased relative hazard of failure compared to those with fewer mutations 
(4-fold), and an increased hazard of failure as body temperature increases 
(by 70% for each °e). In addition there was trend towards a 70% decreased 
relative hazard of failure with higher mg/kg doses of pyrimethamine. 
Table 15 presents the model with treatment group added to the 
subset of risk factors presented in Table 14. The variable "mg/kg dose of 
pyrimethamine" became non-significant and was removed from the model. 
Interaction terms between all the final variables selected were tested and no 
significant interactions were found, indicating that the treatment effect is the 
same for all 
association 
and mutations and for all temperatures. The 
oe't1weem treatment and failure, when modelled with the risk 











Table 15: Time to treatment failure final model, PP dataset 
Variable Hazard ratio 95% CI 
Treatment with AS Ius 0.0-0.7 0.018 
0.3 0.1-0.8 0.022 
3.4 1.3-9.3 0.014 
1.6 1.0-2.4 0.033 
Again, final model was tested with parasite density replacing 
This new model fit was not quite as good as the final model 
chosen and parasite density itself was not statistically significant, although 
was a trend towards signifiGance (p=0.07). 
final model suggests that, in addition to treatment with AS plus SP which 
oec:re;aSE!S the relative risk of treatment by 80% compared with SP 
monotherapy, other important riek factors include being aged over 7 years 
(which the relative risk of failure by 70%), the body temperature 
on Day 0 (which increases the relative risk failure by 60% 
additional °C) and having a quintuple mutation (which the relative 
risk of failure 3.4 fold compared to fewer mutations). results confirmed 










6.4 Secondary outcome analysis: time to parasite clearance 
6.4.1 Intention-to-treat (ITT) analysis 
The analysis of time to parasite clearance included the same dataset as 
the ITT analysis of the primary outcome. One additional subject was 
automatically excluded as he did not have 2 consecutive zero parasite 
densities due to a missed visit. Actual days were used therefore a few 
subjects did not clear parasites until Day 8 or 9. Kaplan Meier estimates 
showed that only 52.0% (95% CI 45.0%;59.3%) of those taking SP 
monotherapy had cleared paraSites by 48 hours compared to 76.3% (95% CI 
69.9%;82.3%) taking AS plus Sp; demonstrating the superior effect of 
plus SP (log rank p<0.001) (Figure 10 and Table 16). 
Survival estimates by treatment group 
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Number at risk 
trt:: SP 192 








Figure 10: Parasite clearance time KM survival curve, ITT dataset 



















A univariate Cox regression model estimating unadjusted treatment 
showed that the relative hazard 'of parasite increased by 90% on 
AS plus SP compared to alone (Hazard ratio 1.9, 1.5;2.3, p<O.001). 
following univariate relationships were found for the other risk factors (Table 
17): 
Table 17: Parasite clearance time univariate analyses of potential risk 
factors, ITT dataset 
Variable Hazard ratio 95%CI 
Age> 7 years vs. age S 7 years 1.3 1.0-1.7 
I Anaemia, presence vs. aUl:>ellve 0.9 0.7-1.1 
Severe anaemia, presence vs. absence 0.7 0.3-1.7 
, AS total dose (mg/kg) 1.0 1.0-1.1 
· Pyrimethamine total dose (mg/kg) • 1.0 0.8-1.2 
Diarrhoea in the first 24 hours post-dose, I 1.0 0.6-1.7 
presence vs. absence during that time I 
Diarrhoea between days 2-7 presence vs., 0.7 0.3-1.4 
• absence on these days . 
Duration of malaria symptoms before Day 0 1.0 0.9-1.0 
(days) 
Gender, male vs. female 0.9 0.8-1.2 
· Haemoglobin Day 0 (g/dL) 1.0 1.0-1.1 
lOg10 parasite density {per ~I blood} 0.7 0.7-0.8 
• Presence of a quintuple mutation vs fewer 0.8 0.6-1.0 
mutations 
Site Catuane vs Boane 1.8 1.2-2.5 
Magude vs E3oal1e 0.8 0.6-1.1 




















Catuane (compared to others) 2.1 1.5-2.9 <0.001 I 
Temperature Da~ 0 (OC) 1.0 1.0-1.0 0.681 
History of vomiting vs. no history of 0.7 0.4-1.0 ' 0.043 
• vomiting 
History of vomiting combined with fever 0.5 0.3-1.0 0.043 
Day 0 vs. no such combination 
Repeat dose of study drug due to vomiting 1.0 0.6-1.6 0.958 
Weight (kg) 1.0 0.99-1.0 0.107 
Use of other drug with anti-malarial activity 0.9 0.6-1.3 0.479 
Statistically S~I:jIl"'''C:'' variables in bold type 
Several multivariate models w~re compared to find the best subset of 
combined risk factors that are predictive of the relative hazard of clearing 
parasites in the dataset (Table 18). The variables relating to concomitant 
with another drug having inherent antimalarial activity and 














analysis, were both not significantly associated with the hazard of clearing 
parasites. 
Table 18: Parasite clearance time best model without treatment, ITT 
dataset 
This table shows a significant ne:gative association between- parasite density 
and the time to parasite clearance, indicating that those subjects with a 
higher baseline parasite density have a decreased relative hazard of clearing 
parasites compared those having lower baseline parasite densities. 
Conversely, subjects enrolled at Catuane have an increased relative hazard 
of clearing parasites. There was a trend towards subjects over 7 years of age 
clearing parasites more rapidly. 
Table 19 presents the model with treatment group added to the selected 
subset of risk factors presented in Table 18. The addition of treatment 
necessitated the removal of the age category variable as it became non-
significant (p=0.133). Otherwise the model did not significantly change and 
the superior treatment effect AS plus SP compared to SP monotherapy in . 
terms of clearing parasites when 'modelled with risk factors was similar to that 
found when unadjusted. 
Parasite clearance time final model, ITT dataset 
These results show that treatment with AS plus SP increases the relative 
hazard parasite clearance by aO% compared with SP monotherapy. Other 
important factors that had an impact include being a subject enrolled at 
Catuane clinic which led to an 80% increase in relative hazard of parasite 
clearance, while each 10 fold in parasite density decreased the 











When interaction terms between all the final variables were tested, a 
significant interaction was found between treatment group and log parasite 
density suggesting that the AS plus SP treatment effect was amplified when 
the parasite density was higher (Table 20). However, the relative hazard of 
clearing parasites was reasonably similar for both treatment groups when 
they were modeled separately (SP: Hazard ratio 0.7 [95% CI 0.6;0.8], AS 
plus Hazard ratio 0.8 [95% CI 0.7; 1.0]) indicating that the global results 
from the final model presented in 
generally. 
19 above holds true for all patients 




0.6-0.8 . <0.001 
1.3- <0.001 












6.4.2 Per-protocol (PP) analysis 
The PP analysis of time to parasite included the same of 
subjects as for the PP analysis of primary outcome, time to treatment 
failure. One additional subject was automatically excluded as he did not have 
2 consecutive zero parasite densities due to a missed visit. Actual days were 
used therefore a few subjects did not clear parasites until Day 8. AS plus SP 
was found to increase the relative risk of parasite compared to SP 
monotherapy (log rank p<O.001) as shown by Kaplan-Meier curves (Figure 
11) and survival estimates (Table 21): 
Survival estimates by treatment group 
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Figure 11: Parasite clearance time KM survival curve PP dataset 
Table 21: Parasite clearance time KM survival estimates, PP dataset 
Time I SP AS plus SP 
(days) 
\ 
N Survivor function N I Survivor function 
(% and 95% CI) I (% and 95% CI) 
10 0 100 0 100 
1 162 79.10 (71.90-84.32) 162 53.70 (45.73 - 61.02) 
2 121 45.71 (37.73 - 53.32) 70 20.71 (14.38 - 27.86) 
3 54 30.47 (22.93 - 38.33) 18 57.5 (2.2 - 11.7) 
·7 26 16.41 (10.0 - 24.2) 3 0.0 













data show that only 54.3% (95% CI 46.7%;62.3%) of those taking SP 
monotherapy had cleared parasites by 48 hours compared to 79.3% (95% CI 
72.2%;85.6%) taking AS plus 
A univariate Cox regression model estimating the unadjusted treatment effect 
showed that the relative hazard of parasite clearance increased by 90% 
AS plus SP compared to SP alone (Hazard ratio 1.9, 95% CI 1.4;2.4, 
p<O.001). following univariate relationships were found for the other risk 
factors (Table 22): 
Table 22: Parasite clearance time univariate analyses of potential risk 
factors, PP dataset 
Variable Hazard ratio 195% CI 
Age> 7 years vs. age S 7 years . 1.5 1.1 - 1.9 
Anaemia, presence vs. absence. 0.9 0.7-1.1 
· Severe anaemia, presence vs. absence 0.5 0.2 - 1.5 
AS total dose (mg/kg) . 1.0 0.9 -1.1 
Pyrimethamine total dose (mg/kg) 1.0 0.7-1.3 
Diarrhoea in the first 24 hours post-dose, 1.0 • 0.6 - 1.7 
presence vs. absence during that time 
Diarrhoea between days 2-7 presence vs. 0.7 0.3 - 1.3 
dbl:le"Ye on these days 
Duration of malaria symptoms before Day a 1.0 1.0 -1.1 
(daY*3) 
Gender, male vs. female 1.0 0.7-1.2 
Haemoglobin Day a (g/dL) 1.1 1.0-1.1 
· Log10 parasite density (per iJl blood) 0.7 0.7 - 0.8 
Presence of a quintuple mutation vs 0.7 0.5 -1.0 
presence of fewer mutations 
· Site Catuane vs Boane 1.8 1.2 - 2.6 
Magude vs Boane 0.8 0.6 - 1.1 
Namaacha vs Boane 0.7 0.5 -1.0 
Catuane (compared to others) 2.1 1.5 - 3.0 
Temperature Day a (OC) 1.0 • 0.1 - 1.0 
History of vomiting vs. no history of 0.6 0.4 - 1.0 
vomiting 
History of vomiting combined with fever Day a 0.5 0.2 -1.0 
vs. no such combination 
Weight (kg) 1.0 1.00 -1.01 
Statistically S~I:IIIIII""ClI" variables in bold type' 
multivariate models were compared to find the best subset of 
combined risk factors that are predictive of the relative hazard of clearing 
































Table 23: Parasite clearance time best model without treatment, PP 
dataset 
Hazard ratio 95%CI p 
0.8 0.7 -0.9 <0.001 · 
1.4 1.1 - 1.8 0.021 
1.8 1 -2.5 0.001 
0.5 0.2 -1.1 0.082 
found in the intention-to-treat the indicates that those 
subjects with a higher baseline parasite density have a decreased relative 
hazard of clearing parasites compared to having lower 
parasite densities, while subjects' enrolled at Catuane and those over 7 years 
of age have an increased relative hazard of clearing parasites. A difference 
found in the analysis of this PP dataset compared to the ITT dataset is that 
we also observed a trend for a negative association between subjects with a 
medical history of vomiting comilined with a fever on Day 0 and the relative 
hazard of clearing 
model fit overall. 
1"<:::uIl!litac:!: The inclusion of this particular variable improved 
Table presents the model with treatment group added to the selected 
subset of risk factors presented in Table 23. The addition of treatment 
decreased the statistical significance of the variable relating to the age 
categories. The variable relating to subjects with a medical history of vomiting 
combined with a fever on Day 0, although not significant itself, was retained 
as its inclusion improved the model overall. The statistically significant 
superior treatment effect AS plus compared to monotherapy in 
terms of clearing parasites when modelled with the risk factors was similar to 
that found when unadjusted. 
Table 24: Parasite clearance time final model, PP dataset 
95% CI P 
1.4 - 2.3 <0.001 
~~~~ __ ~ __ ~==~~~~~~ ______ ~~0~.7_-_0~.=9 __ r<~0~.0~0~1~ 
1.0-1.7 0.046 












Interaction terms between all final variables selected were tested and no 
significant interactions were fo~nd (although trends towards significance 
were observed) indicating that the treatment effect is essentially the same 
regardless of age, site, parasite density and vomiting/fever categories. 
final that treatment with plus SP increased the 
relative hazard of parasite clearance by 80% compared with SP 
monotherapy, In addition, subjects aged over 7 years had a 30% increase, 
and those enrolled at Catuane clinic, had an 80% increase in the relative 
hazard of parasite clearance. Conversely, each 10-fold increase parasite 
density lowered the relative risk of parasite clearance by 20%. 
The only real difference found between the analyses of the two datasets was 
that age over 7 compared to younger was a significant univariate risk 
factor for clearing parasites in the PP dataset and not in the ITT dataset. 
6.5 Secondary outcome analysis: fever clearance 
Any subject who had a fever on Day 0 was included in subset for this 
analysis (n=187, 45.5%). Of these, 89.4% taking SP and 88.2% taking AS 
plus had cleared the fever by Day 1, with 97.9% and 98.9%, respectively, 
clearing parasites by Day Only 1 subject (who was in the AS plus SP 
group) had not cleared fever by Day 3. There was no statistically significant 
difference for the fever clearance. between treatment groups (chi2 p=0.356). 
6.6 Model validation 
The models were built and validated according to the methods described in 
section and a summary is giyen in Appendix 4. In all 4 survival analyses 
were a small selection of Cox-Snell residuals 
predicted and actual observations) that suggested the models did not have 
an ideal fit. In addition, although the proportional hazard assumptions were 
satisfied overall in model, they were not satisfied for the mutation . 
category in the treatment failure models and for the parasite density category 











7.1 Summary of findings 
The aim this study was to provide evidence to Mozambique policy-makers 
regarding the efficacy safety of sulfadoxine-pyrimethamine (SP) with or 
without artesunate (AS) for the treatment of uncomplicated malaria in 
Southern Mozambique. This MPH thesis was limited to the efficacy analysis. 
In a survival analysis restricted to those subjects who complied fully with the 
protocol, both drug regimens were found to efficacious (above 90%). 
However, when AS was combined with the outcome was significantly 
improved with regard to both the relative risks of achieving an ACPR and of 
shortening the time to clearing of peripheral parasites. When data were re-
analysed in an intention-to-treat dataset, the results were almost identical for 
both outcomes. 
The findings of the study are consistent with the literature that combining AS, 
an artemisinin-derivative, with improves efficacy should the efficacy of 
be sufficiently high, as the drugs have independent modes of action. The 
combined efficacy of plus SP was above 95%, the minimum level 
recommended by the WHO necessary for when adopting a new 
policy7. The increased parasite clearance the combination regimen 
corroborates data that show the artemisinins have a much higher parasite 
reduction ratio, in the order of 103-105 parasites per asexual life cycle, 
compared to 10-103 for sulfadoxine-pyrimethamine.35 
A similar risk of re-infection with a new parasite during the 42-day follow up 
period was found for both treatments, which is as expected as is rapidly 
eliminated and both drug arms contained SP. Slowly-eliminated anti-
malarials, such as SP, are responsible for preventing re-infection (post-
treatment prophylaxis), as opposed to more rapidly eliminated artemisinins.36 
The positive impact of using drugs with delayed elimination leading to this 
prophylactic effect has public health importance any malarial episode, 
whether caused by re-infection or is the detriment of the 
individual and the community, and re-infection have relatively greater 











recrudescence is then lower). However, the benefits of this prophylaxis 
needs to be weighed against the risk of increased selection of resistant 
parasites conferred by slowly-eliminated drugs.37,38 
No significant difference was found between treatments with regard to fever 
clearance suggesting that the more rapid clearance of parasites by AS did 
not translate into a better clinical 'T,...,..,.,..,"" relating specifically to As our 
inclusion criteria allowed for a history of fever as well as current fever, 
number of subjects enrolled with fever was limited. Previous studies have 
found the combination of AS plus SP to fever more quickly compared to 
monotherapy, but used different methodology to ours by counting 
reporting a history of fever that remained afebrile as also clearing fever.39 
7.2 Other significant associations with outcome 
Several of the demographic and clinical characteristics modelled with the 
main treatment variables were found to important independent risk factors 
for treatment failure and/or clearance of peripheral parasites in multivariate 
analyses. Possible associations between risk factors themselves make 
interpretations difficult and, despite numerous malaria efficacy studies 
conducted in many regions of the world, few investigate other risk factors 
with which to compare our results. Furthermore, there are known factors that 
influence this complicated disease which we did not assess, or analyse yet, 
such as the developmental stage parasites the time of treatment, 
pharmacokinetic parameters, concomitant medical conditions such as 
HIV/AIDS. 
7.2.1 Age 
Increased age was an important predictor of outcome; those aged over 7 
years were 70% less at risk of treatment failure than those 7 and under and 
were 30% more likely clear parasites more rapidly (the latter found only in 
the per-protocol analysis). These results are consistent with what is known 
about immunity to malaria infection increasing with age, and findings in other 
studies. Repeated exposure to falciparum malaria usually in early childhood, 
unless it causes severe disease and death, results in an acquired partial 
immunity (premunition).40,41 This effect, however, is not understood 










the physiological and environmental risk factors for malaria are entwined 
to the vector (mosquito), host (human subject), and agent (parasite) 
relationships. Immunity is believed to be a combination of anti-disease and 
anti-parasite roles which impact on the severity of disease experienced by an 
individual and the chance of recovery with or without treatment.42 roles 
are age-dependent; anti-disease immunity is generally associated with 
younger (less than 5 years) than anti-parasite immunity 
(adolescent/earlyadulthood).43 
Another hypothesis for associations between lower and poorer treatment 
outcome is physiological c~ncentrations of anti-malarials given at the 
labelled particularly SP, may sub-optimal in younger patients.44,45 
Dosing regimens derived from clinical studies that recruit adults may lead to 
inappropriate recommendations for children particularly if regimens are age-
rather than weight-based, although is more practical in resource-poor 
environments. Moreover, the disposition of drugs in children may altered 
leading to concentrations that are below the therapeutic threshold.46 
Conversely, adults may be under-dosed if they weigh more than the average 
adult in age-based regimens. We found under-dosing of artesunate by mg/kg 
was not with younger probably the dose r.::::.n'II"r'I'::::' 
in our study were weight-based rather than according to the age-based SP 
package inserts. Ultimately, the pharmacokinetic data, which are not included 
in this report, may help explain the differential age-related failure 
7.2.2 Genetic mutations in the falciparum parasite 
Sulfadoxine and pyrimethamine are anti-folate drugs that inhibit the enzymes 
dihydropteroate reductase (dhps) and dihydrofolate· reductase (dhfn 
respectively. KelSIStam::e to develops due to the accumUlation of point 
mutations in the that .::::.n ..... n~l.::::. these enzymes and has been found to be 
associated with treatment failure.47,48 from prevalence surveys 
conducted in Southern Mozambique show as resistance to 
increased between 1999 and 2005, the number of mutations increased in 
parallel, reflecting increased drug pressure and an influx of resistant genes 










In our study the ... "ac-an of a quintuple mutation (dhfr S108N/N511/C59R 
and dhps A437G/K540E) was associated with a more than 3-fold increase in 
the risk of treatment failure compared to fewer mutations. a strong predictor 
of outcome and offering further evidence for the spread of resistance SP in 
this area. Similar observations elsewhere motivated proposals that 
molecular markers of resistance be actively used to predict future therapeutic 
response. Undoubtedly this a useful tool, particularly at the population level 
to the myriad factors playing a role in each individuaL50 However, other 
studies have shown no such associations, presumably due to differences in 
populations or regions (such as host factors, parasite variations or 
transmission dynamics) or study methodology (relating to the follow-up time 
or the laboratory techniques).' signalling the need for further work to 
standardise methodologies in a variety of settings.51 To this end, there has 
recently been a call to action for a global database of both clinical and 
molecular resistance markers which will allow for the standardisation of data 
relating to the associated technology, their analysis and interpretation.52,27 
7.2.3 Body temperature 
The study showed that there was a significant association a higher 
body temperature at baseline anp higher risk of treatment failure. 
The association between fever (both as a single measure baseline and in 
terms of its persistence after treatment) and increased risk of failure has 
been found in other but data are limited (or contradictory), and study 
methodologies are diverse.41 ,53 Moreover. the biological mechanism for the 
association between higher temperature and an risk of failure has 
not been proposed by other authors. 
The role of fever in malaria is not completely understood but it is known to 
mediated by tumour necrosis factor (TNF) that is, paradoxically, as!;OC!latE!d 
with both severe infection and the immune 54 In 
vitro studies show that higher temperatures, analogous to fever'in human 
hosts, may promote the growth of parasites, and high parasitaemias have 
found to increase the risk treatment failure.55,56 There is, however, 
evidence that, in vivo, body temperature and parasitaemia fluctuate 
independently due to sequestration-release, which may be why we did not 










~"',""n""r ... 57 The temperature fluctuations inherent in malaria and the fact 
that temperature may be confounded by other undiagnosed causes of fever 
may indicate it is an inconsistent predictor of outcome, as appears be 
reflected in the literature.41 
7.2.4 Parasite density 
While having a higher parasitaemia at baseline was not seen as an 
independent risk factor for treatment failure in our study, as opposed to what 
has been seen in other malaria efficacy studies, it was a significant factor in 
both datasets' univariate analyses, and was with a delayed 
clearance of after adjustment by treatment, age, site and other 
indicators.of more disease severity (vomiting and fever combined).58 It makes 
intuitive sense that if there are more parasites present then the time to clear 
them will be longer, and thus a greater likelihood parasites remaining after 
drug levels reach a minimum inhibitory concentration leading to their re-
multiplication. There is a greater-chance of a resistant strain being present if 
parasite den~ities are higher.59 The impact of parasite density in our study 
may have been adjusted due to the inclusion of data relating to mutations. 
The interaction that we observed between treatment and parasite density in 
the intention-to-treat analysis of .parasite clearance time suggested that the 
treatment effect was amplified at higher parasitaemias as would be expected 
given the specific indication for artemisinin derivatives in uncomplicated 
hyperparasitaemia.6o However, this interaction did translate into a clear 
difference between treatments. 
7.2.5 Study site 
We found that subjects recruited at Catuane cleared parasites faster 
compared to the other It was not unexpected to find a difference in an 
outcome between sites as, the time study was conducted, disparities in 
their recruitment strategies was noted. Despite information from clinic files 
that Catuane had a high prevalence of symptomatic malaria the 
numbers of cases confirmed by microscopy once the study started was low, 
and it is likely that some cases usually treated that clinic were 
misdiagnosed as a result of their using clinical only. To enhance 
recruitment the study team approached parents of children at a local school 











sites, continued to recruit patients who soug ht treatment 
due to their symptoms. 
While the age of subjects Catuane was not significantly lower compared to 
the other approaching school, there was evidence of 
significantly lower parasite densities and shorter duration symptoms in 
those enrolled Catuane indicating they may suffering from less severe 
malaria infection (although the site effect was still present after adjustment for 
fever combined with a recent history of vomiting, a possible of 
dlSlsaSie severity). Data from surveys in showed prevalence of 
malaria in the community was 92% at Catuane, the highest in Maputo 
Province indicating acquired immunity a young resulting in lower 
parasite densities and clinical symptoms.51 
7.3 Efficacy versus effectiveness of treatment 
This study was to cO,mpare the efficacy of two drug regimens, 
clinical methodology, in general, not offer a good 
representation what happens during clinical practice; eligibility 
criteria are generally too strict, the follow-up of subjects too rigorous and all 
doses are planned to observed. Effectiveness, conversely, to how 
interventions perform in routine clinical settings the myriad 
factors that may impact.52 One such factor is non-adherence whereby 
drug is not taken according to the prescribed recommendations.53 In addition 
may be malabsorption to relevant co-existing pathology or 
vomiting, or concomitant consumption of other drugs that could interfere with 
therapeutic efficacy (and its measurement). effectiveness will be 
over-estimated by efficacy trials. subjects taking part in this study were 
not always withdrawn for protocol violations relating to the mentioned 
above, their data could excluaed or at the time of the violation 
for the per-protocol analysis which could approximate "efficacy" of treatment, 
and then included fully in our intention-to-treat analysis, to offer a more 
pragmatic as~)essment of the "effectiveness", of treatment. The intention-to-
treat analysis is still not truly representative of a clinical practice situation, 
however, as whatever doses were taken were observed, and the follow-up 











7.3.1 Violations relating to dose 
The protocol violations included in this study related mainly to the dose of 
study drug(s) and concomitant use of other drugs with some anti-malarial 
properties. The dose-related violations were that the wrong dose was chosen 
by the clinical team, or a subject did not adhere to the recommended 
schedule to ensure an AS course for 3 days. While protocols allowed for 
repeat dosing of who vomited, this could also be considered as a 
dose-related problem (as it is uncertain how much of the original and repeat 
dose were absorbed). As such, subjects who were re-dosed were also 
removed from the per-protocol analysis, and their impact tested in the 
intention-to-treat dataset. 
Courses of AS shorter than 3 days are not recommended, as they have been 
found to have lower efficacy.13 If shorter courses of AS are combined with 
SP, which is eliminated more slowly and is responsible for complete 
eradication of the parasitaemia, may be more likely to emerge. 10 
SP may, however, be sufficient successfully malaria in individual 
subjects who a substantially reduced of AS should its own efficacy 
be high enough (i.e. when parasites are fully susceptible to SP), as 
demonstrated in this study. 
The impact of mg/kg doses of pyrimethamine and artesunate with regard to 
treatment response are difficult to interpret particularly in the intention-to-treat 
analysis where some subjects had missed doses while others were given a 
repeat dose if they vomited. who did not complete the full course 
AS or who were under-dosed by the study team choosing an inappropriate 
dosing level comprised about 30% of the total protocol violations. Including 
these subjects, and those who were re-dosed, did not substantially change 
the overall treatment response outcomes in terms of risk of failure or paraSite 
clearance. Associations between repeated dose and treatment outcome, 
specifically, were not found to be statistically significant. Ultimately, as 
before, the study results in regard to the effect of dose will be 











7.3.2 Violations relating to concomitant medications with anti-malarial 
properties 
Our study prohibited concomitant treatment with other anti-malarials in order 
to show that treatment outcomes were due to the study drugs and not to their 
use in combination with other drugs that have some antimalarial .QTTlC ...... "C! 
Erythromycin specifically, although not licensed or as an anti-malarial, 
has been found to have weak in vitro and in vivo activity against Plasmodium 
falciparum. 64,65 The retrospective addition of erythromycin to our list of 
prohibited drugs meant that it was actually the predominant contributor this 
subset violations (36/43), however no association was found with 
treatment outcome indicating it did not play a large role in curing 
uncomplicated malaria or the rate of parasite clearance. 
Other concomitant medications that may impact on treatment 
include those that have pharmacokinetic interactions although this was not 
addressed by our study. 
7.3.3 Summary of differences between the per-protocol and intention-
to-treat analyses 
The of our per-protocol and intention-to-treat analyses for primary 
outcome, time to treatment failure, were remarkably similar. Our results were 
robust whether protocol violators were included or excluded. Including data 
from subjects who did not always adhere to dose within this clinical trial 
where the intention was for observed therapy, or who took prohibited 
concomitant medications (e.g. erythromycin), is useful for informing the 
of common practices in treatment 
outcome relating to the relative hazard of clearing parasites the 
independently Significant variables were also very similar the per-protocol 
and intention-to-treat above 7 years was of borderline 




in the per-protocol 
not explained by different 
~"~C!>.Q" and not the intention-to-treat 










7.4 Strengths and limitations, 
In internal validity and reliability of this study was maximised as it 
was designed and managed such that the sample was adequate the 
primary outcome, the quality control and monitoring component was detailed 
and intensive, and the duration of planned follow-up was in line with 
recommendations. Efforts were made to enhance follow up and 
of outcomes considering the study was set poor 
communities with inherent economic migration risk factors. Possible areas 
bias were identified and addressed. Overall the survival analysis 
methodology used, and the inclusion of the intention-to-treat analysis, 
allowed the maximum amount data to be included offering a more 
realistic result compared to logistic against a end point, and 
a per-protocol analysis only.iS 
Non-adherence limited the number of observations within our per-protocol 
analysis although our results were robust as shown by similarity to 
intention-to-treat analysis. Non-adherence is a recognized concern for 
treatments that rely on multiple Qut-patient doses; it been found that the 
number daily doses in a drug regimen is a stronger risk factor for poor 
adherence than socio-economic status.66 The reasons for non-adherence. 
and whether there is an association specifically between adherence and 
outcome, were not explored in this study but it may possible to assess 
adherence in relation to tolerability when the safety are analysed. 
Conversely, if subjects who took AS plus felt significantly better, faster, as 
it decreased parasitaemia more rapidly than monotherapy, may 
not felt need to come back for further doses. Ideally, stUdies should 
incorporate method to measure adherence (such as questionnaires) to help 
understand complex issues, as the reality that stUdies conducted in 
resource-poor settings in particular will have to grapple with related of 
data. As mentioned previously,. our intention-to-treat analysis is not truly 
representative of routine clinical practice (Le. it could not assess the 
"effectiveness" of treatments). 
7.4.1 Duration of follow-up 
A 14 day follow-up for clinical malaria efficacy clinical trials in areas 











recognised the difficulty of longer follow-up in resource-poor settings and 
rationale that initial clinical response was the primary objective to determine 
anti-malarial treatment policy, given the . likelihood frequent re-infection. 
Only 14 days, however, found to be unreliable in determining 
efficacy in any transmission dynamic, and a day follow up is now 
suggested as the minimum due to its superior predictive power, regardless of 
intensity of transmission. Furthermore, has been found that 
which are eliminated slowly should be evaluated for a minimum of 42 days to 
sure of detecting the majority of recrudescences.57 The results from this 
study showed that recrudescence may occur beyond days, albeit in small 
numbers, validating the minimum schedule and suggesting that, should 
resources allow, follow up extended further. 
7.4.2 Quality control and monitoring 
The study was managed by a Principal Investigator and Study Manager (the 
MPH candidate) from UCTs Division of Clinical Pharmacology, both 
experienced in managing clinicaJ trials. It was conducted on site by staff of 
the Mozambique Provincial Ministry of Health who were selected based on 
their experience and training. The teams included medical doctors, medical 
and laboratory technologists and operational management Extensive 
training was given by UCT te~m members to site prior to study 
commencement through workshops addressing the principles of Good 
Clinical and study methodology. monitoring visits by the 
team reinforced this training while case report form data were verified 
against source (original) documentation. Data quality of both Access 
database and Stata files were maximised by extensive cross-referencing 
between fields and the generation of queries almost all of which were able to 
resolved. 
7.4.3 Ascertainment of outcomes and end points 
were made to contact patient who did not return for a follow 
visit and a reason for the loss to follow up noted, if possible, with particular 
attention possible malaria and/or adverse Specific training and 
quality control for key study end points were used for parasitology, 
haematology, medical history, event and concomitant medication, 










recrudescence from re-infection and for mutational analysis. The 
standardised training, methodologies for outcomes' measurements and 
quality control measures taken, especially those relating to parasitological 
end points, minimised the possibility of measurement error. 
It be that the selection of body temperature in the models that 
investigated treatment failure could be reliable compared to 
density, as the latter involved at double slide reading by members of 
study team not involved in assessing clinical response. The use of 
temperature as an indicator for treatment failure would also be compromised 
by the numerous causes of fever and use pyretics. 
Many other factors impact on parasite clearance as a measure for response 
to treatment These include the. immune response of the patient (although 
biological markers are unclear), sensitivity of parasite to the drug, 
stage of the parasite life-cycle at treatment, whether drug being used acts 
at that particular stage, how often measurements are taken, the quality of 
microscopy, the variability of pa~asite density (at lower levels or because 
sequestration) and what drug levels are attained.68,69,35 Unfortunately, most 
of factors are difficult, or sometimes impossible, to standardise or 
incorporate in clinical trials in order to assess their relationships in 
multivariate models. 
7.4.4 
In an study offers advantages over other study designs as the 
random treatment allocation brings it closest to a counter-factual concept and 
there should be no association between the exposure and confounders 
(known or, more importantly, unknown). When subjects are excluded from 
analysis due to data loss (a "per-protocol" dataset), the effect of 
randomisation lost, leading to in the obtained. 
Including all subjects regardless 'of lost data is often preferred but involves a 
decision as to how deal with missing outcomes. Survival analysis, as used 
in this study, maximises available data which are included to the point of loss 
and preserves the randomisation. The results from the intention-to-treat 
dataset being so similar to the . per-protocol dataset that our per-











Allocation concealment was considered sufficient to prevent pre-selection of 
treatment (selection bias) and comparison of baseline characteristics 
demonstrated exchangeability. 
Some risk factors, such as the one which combined a history of vomiting 
within 24 hours prior to enrolment with fever, were collated from 
medical history data and introduced to models retrospectively after a 
subsequent review of the literature suggesting its importance. There is 
debate as to the validity of unplanned analyses, however, these data 
were solicited in a way we do this to a particular 
problem in our study?O 
It was not possible to blind staff to treatment allocation for all measurements 
therefore detection bias could affect some assessments, especially clinical 
outcomes relating to malaria, adverse events and concomitant medication. 
However, the primary end point (treatment failure) was determined 
by a laboratory relating parasite density calculations which is less 
likely be affected by detection bias as laboratory staff were not given 
access to information on treatment allocation. 
7.4.5 Statistical methods used 
While the advantages of survival methods to n~I'v<::'jO malaria efficacy studies 
have been advocated in this report it is apparent that there were some 
problems achieving good model fit and in satisfying all of the assumptions of 
proportional hazards which underpin the Cox regression used. It has been 
suggested that hazard ratios are not appropriate for malaria but, 
despite this, numerous malaria efficacy are analysed and reported 
using the Cox regression. 17 The problems we found in this study are not 
serious enough to invalidate our results; however it must be 
considered that data may from a parametric approach such as an 
accelerated failure time model (AFT).32 
7.4.6 External validity 
While the standard approach taken to the methodology evaluating efficacy 
of malaria treatments allows some comparison between studies, this study 











relating to the malaria parasites (~ncluding mixed infections) and transmission 
dynamics (including seasonality), populations' immunity, pharmacogenetics, 
concomitant and treatments, and parasite resistance patterns. 
However, a statistically significant between SP monotherapy and 
AS plus in this area is consistent with that found in other places with a 
similar SP monotherapy efficacy. 13, 15 
Within the study area itself, eligibility criteria were quite wide and only 
excluded very specific subsets special risk (those under 1 year of age, 
pregnant or seriously ill), so may represent a good proportion of the local 
target populations with uncomplicated malaria. Many malaria efficacy studies 
only include children than 5 years of as recommended by the WHO 
for areas of high intensity malaria transmission. It was felt relevant, however, 
in Southern Mozambique, despite a history of intense malaria transmission, 
to include adults in our study as transmission was rapidly declining, and our 
results show that older patients are at of treatment failure. 
7.5 Public health implications of the study 
The study has public health importance because Mozambique policy makers 
subsequently changed national treatment policy to AS plus SP for 
uncomplicated malaria (implemented in 2007). This decision was based on 
the ACT recommendation from the WHO due to their generally higher cure 
rates, good tolerability, potential to delay resistance and reduced gametocyte 
carriage, and preliminary results available from the studies reported in this 
dissertation. 
It is recognized that any combination with SP may have a limited useful life, 
and acknowledged SP short-comings include inadequate dosing in young 
children.45 It is possible that efficacy has subsequently declined since due to 
dhfr and dhps mutations increasing as a result of a new national 
implementation of SP as intermittent preventive treatment in pregnancy 
during 2007 which is expected to further increase drug pressure and the 
spread of SP resistance, and the of the dhfr 164 mutation, 
associated with high-level pyrim!9thamine resistance, found in neighbouring 











communicated to Mozambique policy-makers by Prof Karen Bames in 2007 
noting further reasons to support a further policy change. 
As mentioned in section 7.2.2 a global database has been proposed in which 
to store data relating to molecular markers of resistance. A similar 
for efficacy outcomes is already ongoing with data study included as 
detailed in the study methodology (section 4.7).27 That initiative, and the 
planned publication of these results which may allow for our data to be 
included in systematic reviews ~r meta-analyses, may contribute to a wider 
public health benefit. 
7.6 Conclusions and recommendations 
This study found that the efficacy of AS plus was superior to that of SP 
alone, which supports the implementation of this combination in Southem 
Mozambique. However, there is a need to consider an alternative 
artemisinin-containing combination due to evidence of drug pressure from 
neighbouring selecting SP resistant parasites, and this likely to 
increase now that SP has been introduced nationally as intermittent 
preventive treatment in pregnancy. 
important risk factors that impacted negatively on treatment failure 
included younger age, p esence' of quintuple dhfr/dhps mutations and more 
severe disease (with temperature as a proxy). Important risk factors 
impacting negatively on the clearance of parasites included, again, younger 
plus higher parasitaemia (an indicator of more severe disease). Age-
related risk factors are thought· to to lower immunity although age-
related dose issues and drug levels may also playing a These 
factors reflect what is known about the disease and should allow those 
involved in treating malaria to be extra vigilant in following up patients who fit 
profiles as they may mare likely to need a second line treatment. 
Survival analysis is a good method for a:S~Stl:::;,:SHlIU the efficacy of malaria 












The inclusion of non-protocol adherent subjects in this study did not change 
" 
the results overall. While it would never be appropriate to advocate that 
ignore protocol violators these results suggest that, should adherence 
be difficult to the results may still be valid. Intention-to-treat and per-
protocol results should be routinely compared to identify factors that impact 

































C6digo do ......... "' ....... '" (exemplo: MOMOOX/MOBOOX): 
AT Endere~o do doente/contacto 
~. ('I N 
Ensuring Effective Malaria Treatment 
Paciente de nascimento (minimo ano): visita: 
Masculino 0 0 
Sim IJ 0 
Exame de resultado ido 0 0 
Hist6ria de febre? 0 0 
Peso: 
EXClUIR 0 DOENTE Idade < 12 meses, peso < 10kg 
Temperatura axilar e·< 31.5 sem antecedents 
Gravida ou amamentando a peito 
e 
Sim 0 Nao 0 
Sim 0 Nao 0 
EXClUIR 0 Cotrimoxazole/chloramphenicol/trimeth prim/tetracyclines 
(doxycycline)/folate/outros anti-maliiricos nos ultimos 1 dias 
ADICIONAR TODOS REMEDIOS A PAGINA DOS MEDICAMENTOS dias) 
malaricos e outros 
Presente a 
EXClUIR 0 DOENTE Deficiencia de G6PD, anteriormente alergico ao remedio. 
Achados na examinacao ffsica(malaricos e outros) 
Diagnose ou sintomas ~ 
EXCLUIR 0 DOENTE Seriamente doente (criterio da WHO) 
OBTER CONSENTO INFORMADO 
Densidade 
pa rasita ria 
(resultado) 




de filtro feito 
EXCLUIR 0 DOENTE .... !:2.,.ft densidade parasitaria > 500,000 
Quantidade 
doente (SP ou 
lacebo 
Registar os detalhes se a 
dose for repetida 
REGISTAR 0 NOME DO DOENTE NA CAIXA DE lOS 
Razao de exclusao: 0 parasitaria d severidade malarica 0 














Data visita Temperatura axilar 
Densidade parasitaria Nfvel Observac;ao de sangue em papel 
filtro 
Pro a moderadamente severa ou a malaria severa? 0 Sim descontinuar D Nao 
Outros remedios tomados ou receitados por si da ultima visita condic;oes I", ... ,,..,,,,,, e outras). 
o Sim adicionar a a ina de medica -0 D Nao 
Acontecimentos adversos (condic;oes maiaricas e outras). 
o Sim adicionar a a ina acontecimentos adversos 0 Nao 
REMEDIOS Dia 1 





A densidade ue 0 resultado do dia o? 
Pro ressao a moderadamente severa ou a malaria severa? 
Outros remedios tomados ou por si desde da ultima 
o Sim adicionar a a ina de medica -0 
Acontecimentos adversos (condic;oes malaricas e outras). 
DISPENSA DE REMEDIOS 2 
o bserva c;ao sangue em papel 
de filtro 
descontinuar IJ Nao 
D Sim descontinuar IJ Nao 
(para condic;oes malaricas e outras). 
o Nao 
Numero do grupo Registe os detalhes se a 









. e a densidade parasitaria como % 
i do Dia O? 
Pro 
Outros remedios tomados ou receitados por si 
o Sim adicionar a a ina de medica - 0 
no sangue 
Acontecimentos adversos (condic;oes malaricas e outras). 
D Sim adicionar a a ina de acontecimentos adversos 
Observac;ao de 






















Acontecimentos adversos (condi~5es malaricas e 






Gametocyte no sangue 














mali3ricas e outras). 
Hemoglobina 
Hemoglobina 
o Sim desc:::ontinuar 0 Nao 
Pro a moderadamente severa ou a malaria severa? 0 Sim descontinuar 0 Nao 
Outros remedios tomados ou receitados por si desde da ultima visita (para condi~5es malaricas e outras). 
o Sim adicionar a a ina de medica -0 DI\lao 
Acontecimentos adversos (condi~5es malaricas e outras). 
parasitaria 
Existencia ":o.':oeit'::. .. i 
Densidade 
Gametocyte no sangue 
Pro ressao a moderadamente severa ou a ' .. A .......... 
Outros remedios Inrn.u""" 
o Sim adicionar a 
Acontecimentos :::If1\It:> .. 't::.n..: 





























Outros remedios tom ados ou receitados por si desde da 
o Sim adic:ionar a a ina de - 0 . 
visita (para condi~5es malaricas e outras), 
o Nao 
Acontecimentos adversos (condi~5es malaricas e 
o Sim adic:ionar a a ina de acontecimentos adversos 0 Nao 
I'1n.<:l,nrO for descontinuado de a aqui 0 falha parasitol6gica 
o deteriora~ao clfnica 
o acontecimento adverso/acontedmento adverso serio 
o doente/pedido do do doente 
o perdido para seguimento 
o falha investigativa 
o outro: 












Acontecimentos Adversos (desde do dia 0) 
Descric;ao Serio Datas de comec;o e tim Em progresso no 
SIN tim do estl~do 
(marque) 
. 
*categories serias: Marte do doente 
Doente viti rna de acontecimento adverso com perigo de 
Doente tornou-se bastante incapacitado 
Medicac;ao (S/N) 
Gunte a tabua 
seguinte) 
Doente foi hospitalisado( ou hoSpitalisac;ao fOi prolongada )durante a estudo 
engravidou durante 0 estudo 
Tunisia Camba (Gerente Local): 082456497 
Dr Barnes (Investigadora Principal): + 27 21 406 6758/+ 440 
Liz Nettleship (Gerente SA): + 214066758/+ 6794915 
Lauren Hill SA): + 214066758/+27827852053 
Tracey Fourie (Assistente da Dra : + 27 406 6758/+ 27 83 400 1922 
Dr Ushma Mehta de Seguranc;a): + 773 1440 
'Medica<;:ao(de 7 dias antes do dia 0 e durante a estudo) 
Nome do Datas de inicio e tim Em progresso Dose Razao de uso 




























University of Cape Town
SEACAT in vivo ASSP SP CRF Moz 141003 
MH Medical history clinical dICl!:lllu::>l::> or symptom Started 
n __ .1. ,_-i Ongoil (tick) Medication taken*? ',", 






'* Olo...,~a in the 




····FOrm ,... -' Stopped OLc:1Illt:::U 
ddmmyy , ddmmyy U~~~c~;19 





















:::: four times a PRN :::: 
ToS :::: three times a 
Bo twice a 
:::: once a day 
ON:::: at night 
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1 Primary outcome: time to treatment failure 
1.1 dataset 
.8 
Cox-Snell residuals suggest model fJt problems 
Potential influential observations were identified as: 
., M082004_012, MON2003_013 (temperature) 
., M082004_053, MOM2004_080, MOM2004_191 (age) 
., MOM2004_190 and temperature) 
., MON2003_048, MOM2004_167, MOM2004_193 (age treatment) 
., MON2003_051 (temperature and treatment) 
., M082004_049 temperature treatment) 
MON2003_048 was dropped as had a clinical deterioration on Day 1 
despite the profile suggesting treatment success. 
Overall the proportional hazard ass\lmption was satisfied (Schoenfeld p=0.1075) but 
not for the mutation category (Schoenfeld p=0.0368) 
1 PP dataset 
Cox-Snell residuals suggest model fit problems 
Potential influential observations were identified as: 
., M082004_012, MON2003_013 (temperature) 
., M082004_053 , 
., MON2003_048, MOM2004_190, MOM2004_1 (treatment and age) 
., M082004_049 (temperature and age) 
Subject MON2003_048 was dropped as had a clinical deterioration on Day 1 
despite his profile suggesting treatment success. 
Overall proportional hazard assumption was satisfied (Schoenfeld p=O.6572) but 











2 Secondary outcome: time to parasite clearance 
2.1.1 ITT dataset 
Cox-Snell residuals suggest model f1t problems 
Potential influential observations were identified as: 
• MON2003_051 (parasite density) 
• MOC2003_011 and treatment) 
Both were dropped. MON2003_051 was an ETF Day 3 however parasite 
was 32% of a very low Day 0 resulf(47 parasites per ~I blood). MOC2003_011 took 
longer to compared to what would be taken the profile. 
Overall the proportional hazard assumption was satisfied (Schoenfeld p=O.0677) but 
not for the density category (Schoenfeld p=O.0123) 
2.1.2 dataset 
'"" 
Cox-Snell residuals suggest model fit problems 
Potential influential observations were identified as: 
• MON019 (age) 
• MOC011, (site) 
• MOC032 (parasite density, and site) 
• MOB060 (History of vomiting combined with fever) 
No subjects were removed from 
The proportional hazard assumption was satisfied both overall and for variables 












1Greenwood BM, Bojang K, Whitty CJM, Targett GAT. Malaria. Lancet 
2005;365:1487-98. 
2World Health Organisation. The Malaria Report 2006 [cited 2008, Apr 4]. 
Available from: http://www.afro.who.intlmalaria/publications/annuaLreports/africa_ 
malaria_report_2006.pdf 
3Snow RW, Omumbo JA, Molyneux Obiero JO, Relation 
between severe malaria morbidity in children and level of Plasmodium falciparum 
transmission in Africa. Lancet 1997;349 (9066):1650-54. 
4Centers Disease Control. Malaria. [cited 2008, Arp . Available from: 
http://www.cdc.gov/malaria/index.htm 
5Chilundo B, Sundby J, M. Analysing the quality routine malaria data in 
Mozambique. Malar J. 2004;3:3. 
6Sharp BL, Kleinschmidt I, Streat Maharaj R, KI, Ourrheim DN .......... ,., ... " 
of regional malaria control collaboration-Mozambique, South Africa and 
Swaziland. Am J Trop Med Hyg. 2007;76(1 
7World Health Organisation. Guidelines for the treatment of malaria 2006. 
WHO/HTM/MAU2006.1108. 
80rakeley CJ, Secka I, Correa Greenwood BM, GA Host hematological 
factors influencing the transmission of Plasmodium falciparum gametocytes to 
Anopheles gambiae s.s mosquitoes. Med Int Health. 1999;4:131-8. 
9Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001 ;184:770-
76. 
10Nosten F White NJ. Art misinin-based combination treatment of falciparum 
malaria. Am J Trop Med Hyg. 2007; 77(6):181-92 
RN, Nosten Luxemburger C, ter Kuile Paiphun L, 
Chongsuphajaisiddhi T et Effects of artemisinin derivatives on malaria 
transmissibility. 1996; 1654 - 8. 
12Price Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F aL 
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J 
Trop Med Hyg. 1 60:1019-
1~on Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebech Gosling R. Efficacy 
of artesunate plus pyrimethamine-sylphadoxine for uncomplicated malaria in 
Gambian children: a double-blind, randomised, controlled trial. Lancet. 2000; 
14Rapid responses Plowe CV, Kublin JG Dzinjalamala FK, Kamwendo OS, 
Mukadam RA, Chimpeni P et Sustained clinical efficacy of sulfadoxine-












line treatment: five year prospective.study. BMJ. 2004;328(7439):545-8. Epub 2004 
2. 
15 Adjuik M, Babiker A, P, Olliaro P, Taylor W, White N: International 
Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-
analysis. Lancet. 2004;363(9402):9-17. 
16 Taylor W, White NJ. Antimalarial drug toxicity: a review. Drug Safety 
2004;27(1):25-61. 
17 Stepniewska K, White NJ. Some considerations in and interpretation of 
antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127. 
18 World Health Organisation. ASlsessm,ent and monitoring of antimalarial drug 
efficacy for the treatment of uncomplicated falciparum malaria. 2003. 
WHO/HTM/RBM/2003.50. 
19 Guthmann Pinoges Checchi F, Cousens S, Balkan van Herp M al. 
Methodological issues in the assessment antimalarial drug treatment: analysis of 
13 in eight African countries-from 2001 to 2004. Antimicrob Agents 
Chemother.2006;50(11 Epub 2006 
20 K. An open In Vivo drug study (with both single and parallel group 
components) to evaluate combination anti-malarial therapy in terms of 
therapeutic efficacy, prevalence of gametocyte carriage and prevalence of molecular 
markers associated with resistance in uncomplicated Plasmodium falciparum 
infections. Including Amendment 4 (Dec 20 karen.barnes@uct.ac.za. 
21 Barnes K. An open-label, randomized, parallel group in vivo drug study to 
evaluate a combination anti-malarial therapy (CAT), artesunate and 
pyrimethamine (ASSP) v rsus sulfadoxine-pyrimethamine (SP) in terms of 
therapeutic efficacy, prevalence of gametocyte carriage prevalence molecular 
markers associated with resistance in uncomplicated Plasmodium falciparum 
IMTii:'I'TII"IMc. (Oct 8 2003). karen.barnes@uct.ac.za. 
22 World Organisation. Assessment of therapeutic <:>"',,..."",.,,, of antimalarial 
drugs for uncomplicated falciparum malaria in areas with intense transmission 1996. 
WHO/MAU96. 1 077. 
23 Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJD, Watkins WM 
Reduction of the of antifolate antimalarial therapy by folic acid 
supplementation. Am J Trop Med Hyg. 2005;73:166-70. 
24 World Health Organisation. Severe falciparum malaria. Trans R Soc Trop Med 
Hyg 2000; 94(1):62. 
25World Health Organisation. 
Guide.1991. 










Genotyping in the As:sessment of 
Recrudescence or Reinfection after Antimalarial Drug Treatment. Parasitology 
Today_ 1998; 14 (11): 462-7. 
27Price RN, Dorsey Ashley Barnes KI, Baird JK, d'Alessandro U et al. World 
Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malar J. 
2007; 6:119. 
28World Health Organisation. International Statistical Classification of and 
Related Problems 10th Revision Version for 2007. Available from: 
http://www.who.inUclassifications/appslicd/icd10online. 
29Division of Pharmacology, of Health Sciences, University of Cape Town, 
editors. South African Medicines Formulary Sixth Edition. Health and Medical 
Publishing Group the South African Medical Association. 
30Department of Health 2000. Guidelines for good practice in the conduct of clinical 
trails in South Africa. Department of Health, Pretoria, South 
31Medical Research Council. Guidelines on ethics for medical research: 
principles. (4th edition). Medical Council South Africa, Tygerberg, South 
Africa. 
32Collett D. Modelling survival in medical r/:llQ:/:ll!:illrl"'l"'I 2nd Chapman and 
Hall/CRC.Press 2003. 
33Nosten ter Kuile Chongsuphajaisiddhi Luxemburger C, Webster HK, 
Edstein M et al. Mefloquine-resistant falciparum malaria on the Thai-Burmese 
border. Lancet. 1991; 337(8750):1140-3. 
Adedeji A Gbotosho Happi Bamgboye AE et 
Predictors of the of treatment, with pyrimethamine-sulfadoxine in children with 
uncomplicated falciparum malaria. Acta Tropica 2006; 98(1):6-14. 
3White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in 
vivo. Minireview. Antimicrob Agents Chemother. 1997;41(7): 141 
36White NJ. How antimalarial drug "" ..... " ..... 
Malar J. 2008;7:9. 
prophylaxiS 
37Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with 
pyrimethamine-sulfadoxine: selective for resistance is a function of long 
elimination half-life. Trans R Med Hyg. 1993;87(1):75-8. 
38Checchi F Piola Fogg Bajunirwe Biraro Grandesso F et al. Supervised 
versus unsupervised antimalarial treatment with artemether-Iumefantrine: 
pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 
2006;19;5:59. 
39Tjitra E, Suprianto Currie BJ, Morris Saunders JR, Anstey NM. Therapy of 










sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, 
Indonesia. Am J Trop Med Hyg. 2001 ;65(4):309-1 
4°Aponte JJ, Menendez C, Schellenberg Kahigwa Mshinda H, Vountasou Pet 
al. interactions in development of naturally acquired immunity to 
Plasmodium falciparum and its clinical presentation Med. 2007;4(7) Erratum 
in: PLoS Med. 2007;4(1 
41 Dorsey G, Kamya MR, Ndeezi Babirye IN, Phares CR, Olson al. 
Predictors chloroquine treatment failure in children and adults with falciparum 
malaria in Kampala, Uganda. Am J Med Hyg. 2000; 62(6):686-92. 
42Enevold A, Nkya WM, Theisen M, Vestergaard LS, Staalsoe et al. 
Potential impact of host immunity on malaria treatment outcome in Tanzanian. 
children infected with Plasmodium falciparum. Malar J. 2007; 16;6: 1 
Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination the 
processes driving the acquiSition of immunity to malaria using a mathematical 
transmission model. PLoS Com put Bioi 2007;3(12): 
44Terlouw OJ, Courval .. IM, Kolczak MS, Rosenberg OS, 0100 AJ, PA 
history and treatment dose are important determinants of sulfadoxine-
pyrimethamine in 1"1"11,,"1''::.1''1 with uncomplicated malaria in Western Kenya. J 
Infect Dis. 2003;187,467-76. 
45Barnes Kif Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-
pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin 
Pharmacol Ther. 2006; 80(6): 582-96. 
46Sarnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug 
resistance. Trends Parasitol. 2008 Mar;24(3): 127 -34. 
47Plowe CV, Djimde A, Nwanyanwu Watkins WM, Winstanley PA 
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate 
synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use 
.. "".,."<>T"' .... I"''''' J Dis. 1997;1 1590-6. 
48Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese Martino LM 
et aL Molecular markers for failure of sulfadoxine-pyrimethamine chlorproguanil-
dapsone treatment of Plasmodium falciparum malaria. J Infect 
2002; 185(3):380-8. 
49Raman J, Sharp B, Kleinschmidt I, Roper C, Streat E, Kelly Vet Differential 
effect of regional drug pressure on dihydrofolate reductase and dihydropteroate 
synthetase mutations in southern Mozambique. Am J Trop Med Hyg. 
2008;78(2):256-61. 
50Taiisuna AO, Nalunkuma-Kazibwe A, Langi P, Mutabingwa TK, Watkins WW, Van 










dihydropteroate synthase gene pred.ict sulphadoxine-pyrimethamine parasitological 
failure in Ugandan children with uncomplicated falciparum malaria 
Genet 2004;4(4):321 
51J. Eriksen Mwankusye S, Mduma MI, Veiga A, Kitua Tomson MG al. 
Antimalarial resistance and DHFRlDHPS genotypes of Plasmodium falciparum three 
after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural 
Tanzania Trans. R Soc Trop Med Hyg. 2008;102:137-42. 
52Plowe CV, Roper C, Barnwell JW, Happi CT, HH, Mbacham Wet al. World 
Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant 
malaria. Malar J 2007;6:121. 
53Hamer DH, Macleod Addo-Yobo Duggan CP, Estrella B, WW et al. 
Age, temperature, and parasitaemia predict chloroquine treatment failure and 
anaemia in children with uncomplicated Plasmodium falciparum malaria. Trans R 
Trop Med Hyg. 2003;97(4):422-8. 
54Kwiatkowski D, Bate CA, Scragg IG, Beattie P, Udalova I, Knight JC. The malarial 
fever response--pathogenesis, polymorphism prospects for intervention. Ann 
Trop Med Parasito!. 1997;91 
55Pavithra Banumathy Joy 0, Singh V, Tatu U. Recurrent fever promotes 
Plasmodium falciparum development in human erythrocytes. J Bioi Chern. 
2004;279(45):46692-9. 
56Sowunmi A, Adedeji AA, Fateye BA, Babalola Plasmodium falciparum 
hyperparasitaemia in Risk factors, treatment and 
gametocytaemia following treatment. Parasite. 2004; 11 {3):317 -23. 
57Del!ey V, Bouvier P, Br slow N, DGumbo 0, Sagara I, Diakite M al. What a 
Single determination of malaria parasite density mean? A longitudinal survey in Mali 
Tropical Medicine & International Health. 2000;5(6):404-12. 
58Fontanet Al, Walker AM. Predictors of treatment failure in multiple drug 
falciparum malaria: results from a follow-up of patients in Eastern 
Thailand. Am J Trop Med Hyg. 1993;49(4)465-72. 
Kuile Luxemburger C, Nosten F, Thwai Kl, Chongsuphajaisiddhi T, White 
NJ. Predictors of mefloquine treatment failure: a prospective study of 1590 patients 
with uncomplicated falciparum malaria. Trans R Trop Med Hyg. 1995; 660-
664. 
6°luxemburger Nosten Raimond SD, Chongsuphajaisiddhi T, NJ. Oral 
artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. 
Am J Trop Med Hyg. 1995;53(5):522-5. 











RA, Nissman D, Lohr KN, Carey Criteria for 
distinguishing effectiveness from efficacy trials in systematic Technical 
Review 12 (Prepared by the RTI-International-University of North Carolina 
Evidence-based Practice Center under Contract No. 290-02-0016.) 2006. AHRQ 
Publication No. 06-0046. Rockville, MD: Agency for Healthcare and 
Quality. 
63Smithuis F, Kyaw MK, 0, Aye KZ, Htet t, M al. Efficacy and 
effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in 
falciparum malaria: an open-label randomised comparison. Lancet 
.2006;367(9528):2075-85. 
64Nakornchai Konthiang Activity of azithromycin or erythromycin in combination 
with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. 
Acta 2006;100(3):185-91. 
65Hamel MJ, Holtz T, Mkandala KaimUa N, Chizani N, Bloland P al. Efficacy of 
trimethoprim-sulfamethoxazole ........... "' .. "',l"I with sulfadoxine-pyrimethamine plus 
erythromycin for the treatment of uncomplicated malaria in children with integrated 
management of childhood illness dual classifications of malaria and pneumonia. Am 
J Med Hyg. 2005;73(3):609-1 
C, Bangsberg D, M, Wood Adherence is not a barrier to successful 
antiretroviral therapy in Africa: AI 2003;17(9):1369-75. 
67Stepniewska K, Taylor WR, Mayxay M, Smithuis Guthmann .. IP et al. 
vivo of drug efficacy against plasmodium falciparum duration of 
follow-up. Antimicrob Agents Chemother. 2004;48(11):4271-80. 
6!lHugosson Montgom ry Premji Z, Troye-Blomberg M, Bjorkman A. Higher 
IL-10 are associated with effective clearance of Plasmodium falciparum 
Parasite Immunol. 2004;26(3): 11 17. 
69Gregson A, PLowe CV. Mechanisms of resistance of malaria paraSites to 
antifolates. Pharmacol 2005;57:117-45. 
7°Vandenbroucke J P. Observational' research, randomized and two of 
medical science. Med. 2008 11 ;5(3):e67. 
71Alker AP Mwapasa V, Purfield A, SJ, Molyneux ME, Kamwendo 
Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil 
resistance in Plasmodium falciparum isolates Blantyre, Malawi. Antimicrob 
Chemother. 2005;49(9): 9-21. 
88 
